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Abstract
A PRETARGETED SPECT IMAGING STRATEGY EMPLOYING
TECHNETIUM-99M BASED ON BIOORTHOGONAL DIELS-ALDER CLICK CHEMISTRY
by
Justin Walsh
Advisor: Lynn Francesconi

A series of related N3S 99mTc-peptide complexes were synthesized and tested for use in
pretargeting SPECT imaging that utilizes the bioorthogonal Diels-Alder click reaction between
tetrazine (Tz) and transcyclooctene (TCO). The objective was to optimize the excretory
pathways of the 99mTc-peptide complexes for maximum tumor targeting with the in vivo “click”
and minimum non-target uptake. The 99mTc–tetrazine constructs were prepared by reaction of
99m

Tc-peptide complexes (99mTc-FKC, 99mTc-FKCR, 99mTc-DKC, and 99mTc-SKC) with Tz-NHS

or Tz-PEG5-NHS to form 99mTc FK(Tz)C, 99mTc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and
99m

Tc-SK(PEG5-Tz)C. Log P values were obtained to determine hydrophilicity of each complex.

Bovine serum albumin (BSA) was modified with TCO, reacted with each complex, and the
“click” reaction was confirmed using Radio-TLC. Biodistributions and blood half-life studies
were then performed on healthy athymic mice to determine which complex exhibited the optimal
excretory characteristics. The Radio-TLC results indicate that each complex contains a viable Tz
moeity. The biodistribution results suggest that 99mTc-FK(PEG5-Tz)CR has the most promising
excretory pathway wherein excretion through the gut and intestines is minimized. The blood
half-life values obtained indicated that clearance from the blood is not likely too fast to prevent
iv

the in vivo “click” reaction from occurring. Mice bearing xenografted SW1222 tumors were
pretargeted with A33-TCO followed by the 99mTc-peptide-Tz complexes. SPECT/CT images
were obtained and the in vivo “click” was confirmed for both 99mTc-FK(Tz)C and 99mTcFK(PEG5-Tz)CR. 99mTc-FK(PEG5-Tz)CR exhibited higher tumor:background ratios than did
99m

Tc-FK(Tz)C but had too high intestinal uptake for translation to the clinic.
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Chapter 1
Pretargeting

1

1.1. Pretargeting General Background
Ever since Sam Seidlin demonstrated the potentially life-saving benefits of nuclear
medicine in 1946, scientists and physicians have been actively working to expand the availability
and efficacy of these treatments.1 When the technetium-99m generator (99Mo/99mTc) was
developed in the 1960s, it allowed 99mTc to develop into the ubiquitous imaging agent that it is
today. Both the therapeutic and diagnostic sides of nuclear medicine have come a long way over
the decades and the range of radioisotopes considered for clinical use continues to expand.
Among the isotopes commonly used in nuclear medicine are 99mTc, 123I, 131I, and 111In for singlephoton emission computed tomography (SPECT) imaging, 13N, 18F, 68Ga, 89Zr, and 82Rb for
positron emission tomography (PET) imaging, and 90Y, 131I, and 177Lu for therapy. Many others
have been used in niche applications and/or are undergoing continued study for future production
and use.
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Selection of Radioisotopes for Nuclear
Medicine Imaging
Radionuclide
111

In
I
131
I
133
Xe
201
Tl
67
Ga
99m
Tc
11
C
124
I
13
N
15
O
18
F
38
K
62
Cu
64
Cu
68
Ga
82
Rb
89
Zr
123

Half-life

Imaging Type

2.80 d
13.2 h
8.02 d
5.25 d
3.05 d
78 h
6.01 h
20.3 m
4.18 d
9.97 m
122.24 s
109.7 m
7.64 m
9.67 m
12.7 h
68 m
1.27 m
78.41 h

SPECT
SPECT
SPECT
SPECT
SPECT
SPECT
SPECT
PET
PET
PET
PET
PET
PET
PET
PET
PET
PET
PET

Table 1: Selection of common radioisotopes used for nuclear medicine imaging.
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Selection of Radioisotopes with Therapeutic Potential

64 h

Primary
Therapeutic
Decay Mode
β-

67

Cu
188
Re
186
Re
177
Lu
131
I
225
Ac

61 h
17 h
90 h
161 h
8.02 d
10.0 d

β
β
βββα

223

11.4 d
0.76 h
1.01 h
7.21 h
67 h

α
α
α
α
Auger

Radionuclide
90

Y

Ra
Bi
212
Bi
211
At
111
In
213

Half-life

-

Table 2: Selection of common radioisotopes with therapeutic potential.

Although some radiopharmaceuticals, mostly imaging agents, do not need targeting
vectors and rely only on their natural biodistribution, e.g. 99mTc sestamibi has high cardiac
uptake and is therefore used to image the heart, radiolabeling specific targeting vectors can
expand the number of available targets while improving image quality and/or therapeutic
outcomes. Chief among targeting vectors are monoclonal antibodies (MAbs), which can be
humanized to avoid immunogenic response and are highly specific to a given antigen. Although
directly radiolabeled MAbs can be used to great effect for imaging, radioimmunoguided surgery,
and radioimmunotherapy, MAbs’ long serum half-lives mean that only isotopes with multi-day
physical half-lives are appropriate.2 This leads to the primary justification for pursuing
pretargeting strategies. By decoupling the longer circulating MAbs from the radioisotope, shorter

4

lived isotopes (e.g. 64Cu and 99mTc) can be used without delivering too high a dose to the patient.
Furthermore, non-target dose can be minimized while high target uptake is maintained,
regardless of the radioisotope used. To appropriately introduce the pretargeting system employed
in this work, an in-depth review of pretargeting in general is in order. Although several excellent
pretargeting reviews have been published, this introduction will seek to synthesize and expand
on these, providing the necessary context for evaluating the benefits and limitations of the
subsequent research results.2-4
Do you think you should introduce pretargeting here in more detail than just the above sentences.

1.2. Streptavidin and Biotin
One of the earliest pretargeting systems developed made use of avidin/streptavidin and
biotin. Before looking more closely at the effectiveness of this system, it is worth laying out
some details about its components.
Biotin is a 244-D vitamin found in low concentrations (~2000 fmol/ml) in tissue and
blood.5 Clinical interest in developing better assays for measuring in vivo biotin levels increased
after biotin-responsive inborn errors of metabolism and biotin deficiencies during parenteral
alimentation were highlighted in the literature.5 Both earlier and improved biotin bioassays made
use of avidin, a 66-kD tetrameric protein found in the egg whites of birds, reptiles, and
amphibians.5-6 Each of avidin’s homotetrameric subunits forms an extremely powerful bond with
biotin with an association constant of 10-15 M.6 Both the rapidity of this interaction and the
stability of the resulting bond meant that avidin and biotin were a natural choice for early
pretargeting efforts.

5

Streptavidin is a 60-kD tetrameric protein found in Streptomyces avidinii with an
association constant (10-15 M) comparable to that of avidin.7 Notably, streptavidin is not
glycosylated and therefore shows lower non-specific binding to tissues than avidin.6, 8-9 This
advantage has led to more clinical trials being undertaken with streptavidin than with avidin.10-11
With this said, streptavidin shares the potential for a negative immunogenic response with avidin
given that both are foreign proteins that cannot be humanized, which limits the potential for
repeated treatment in the clinic.12
Around the same time that avidin/streptavidin and biotin pretargeting systems were being
explored, an alternative strategy was considered wherein MAbs were modified with biotin
moieties (biotinylated-MAb), radiolabeled, injected into patients, and then after some time avidin
was used to clear the remaining activity from the blood.13 This method was tested in the clinic
with twenty patients suffering from primary or recurrent colorectal cancer.13 Thirteen patients
were treated with one 123I-biotinylated-MAb, FO23C5 (anticarcinoembryonic antigen), and
seven patients were treated with another 123I-biotinylated-MAb, B72.3 (antitumor-associated
glycoprotein 72), before treatment with cold avidin (48 hours post MAb injection and then again
one to two days before undergoing Radioimmunoguided Surgery (RIGS)).13 This strategy
successfully reduced the circulation time of the radioactive agent and allowed patients to
undergo RIGS one week after MAb injection, as opposed to four weeks when directly labeled
MAbs were allowed to clear on their own.13 Although this demonstrated the benefits of including
avidin/streptavidin and biotin in targeting regimes by allowing sooner RIGS and reducing nontarget dose, both of these benefits were further improved with pretargeting.
Pretargeting with avidin/streptavidin and biotin has been performed using both a two-step
and three-step protocol. The two-step protocol involves modifying a MAb with either a biotin
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moiety or avidin/streptavidin moiety (avidinylated/streptavidinylated-MAb). The modified MAb
is injected into the patient, followed some time later by the corresponding radiolabeled
avidin/streptavidin or radiolabeled biotin (Figure 1 and Figure 2). This method was also tested
with fifteen patients with ovarian carcinoma.14 They were injected with 2 mg biotinylated-MAb,
MOv18 (folate receptor α MAb), followed by 100-150 μg 111In-radiolabeled streptavidin (280370 MBq/mg) three to five days later.14 The tumors were imaged 2 to 48 hours after the final
injection and underwent surgery an average of 3 days later.14 The tumor to non-target uptake of
9:1 for intraperitoneal samples and 45:1 for extraperitoneal samples represented improvements
over standard targeting methods.14 Additionally, one animal study showed a total increase in
%ID/g from 6% for directly radiolabeled MAbs to 24% for biotinylated-MAbs and radiolabeled
streptavidin while another showed significant improvements in metastasis:blood ratios.15-16

7

Figure 1: Pretargeting with biotinylated-mAb and radiolabeled avidin/streptavidin.
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Figure 2: Pretargeting with avidinylated/streptavidinylated-mAb and radiolabeled biotin.

Despite the benefits of using pretargeted biotinylated-MAbs and radiolabeled
avidin/streptavidin over directly labeled MAbs, the alternative arrangement was found to be
preferable. A pharmacokinetic examination of both approaches revealed that maximum molar
concentrations of radioisotope are obtained on the tumor much more quickly for radiolabeled
biotin pretargeted with streptavidinylated-MAbs than for radiolabeled streptavidin pretargeted
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with biotinylated-MAbs or directly radiolabeled MAbs.17 Supporting this result, the clinical
efficacy of radiolabeling the biotin was demonstrated in ten patients with squamous cell
carcinoma of the lung.18 These patients received 1 mg of streptavidinylated-MAb, HMFG1
(human milk fat globule antigen 1), followed by 50 or 1000 μg 111In-radiolabeled biotin two to
three days later.18 Images were able to be obtained within 2 hours of 111In-biotin administration
and non-target uptake was reduced across the board.18 Notably, there is always a concern that
endogenous biotin will saturate the binding sites of the streptavidinylated-MAbs, blocking the
subsequent radiolabeled biotin. In this case, however, the authors determined that the biotin
binding capacity of the circulating streptavidinylated-MAbs was not saturated by endogenous
biotin in three out of four of the patients after one to three days.18 Despite these findings, the
potential importance of clearing endogenous biotin for this type of protocol has been highlighted
in the literature.2
One group used a biotin-galactose-human serum albumin clearing agent between
treatment with streptavidinylated-MAbs and 90Y/111In-biotin for pretargeted radioimmunotherapy
(PRIT).19 Despite showing that their PRIT strategy improved tumor:background ratios over
standard radioimmunotherapy (RIT), these investigators noted that the binding capacity of the
prelocalized streptavidinylated-MAbs decreased over time.19 Interestingly, they asserted that this
was not caused by endogenous biotin, but rather by biotin released from the liver after
metabolism of the clearing agent.19 While this theory was not tested further and is far from
certain, it highlights a potential complication with trying to improve the two-step protocol using
a clearing agent.
The three-step protocol involves 1) injection of a biotinylated-MAb, 2) injection with
avidin/streptavidin, and 3) injection with a radiolabeled biotin (Figure 3). In the first step, the
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biotinylated-MAb will be allowed to circulate for long enough to achieve maximum tumor
localization.20 Since maximum localization occurs before sufficient blood clearance, the second
step is necessary to clear circulating biotinylated-MAbs by promoting metabolism of the avidinbiotinylated-MAb complex in the liver.20 This is known as the “chase effect” and was shown to
be effective in earlier animal studies.21 The second step will also see the tumor-bound
biotinylated-MAbs avidinated, allowing for subsequent targeting with radiolabeled biotin as the
third and final step.20 This not only circumvents the issues with using radiolabeled
avidin/streptavidin, i.e. long circulation times, but also allows cross-linking at the tumor site,
promoting retention and internalization of the radioisotope. This strategy takes advantage of the
tetrameric nature of avidin/streptavidin and significantly reduced tumor to background ratios in
animals imaged with 123I.15
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Figure 3: Three-step protocol using biotinylated-MAb, avidin/streptavidin, and radiolabeled biotin.
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The three-step protocol was tested in humans in multiple studies. The first was performed
with 20 colorectal cancer patients who were 1) injected with 1 mg biotinylated-MAb, FO23C5,
2) injected with 4-6 mg cold avidin 3 days later, and then 3) injected with 0.2-.3 mg 111In labeled
biotin (2-3 mCi) 48 hours later.20 All metastases were successfully imaged and the potential
clinical benefits were clearly demonstrated.20 It was also found to be effective in seven patients
with uveal melanoma, improving diagnostic sensitivity over directly radiolabeled MAbs and
exhibiting lower background activity.22 This study used 1 mg biotinylated-MAb, 224-28S (antimelanoma antibody), for step one and 99mTc-PAO-biotin (20 mCi) for the third step.22 The
improvements in resulting clinical SPECT imaging were confirmed with a larger cohort of 15
uveal melanoma patients.23
Moving beyond imaging, the three-step protocol successfully facilitated RIT treatment. A
test case with a patient diagnosed with advanced oropharyngeal cancer, T4N3M0 squamous cell
carcinoma, who was treated with 1) 10 mg biotinylated-FO23C5 and 20 mg biotinylated-B72.3,
2) 50 mg streptavidin 36 hours later, and 3) 1 mg 90Y-biotin (70 mCi) showed notable response
to treatment with no acute allergic reaction to the MAbs or streptavidin.24 Expanding on this
promising result, 48 patients with high grade (grades III or IV) glioma were treated with
biotinylated anti-tenascin MAbs, avidin and streptavidin, and 90Y-biotin using comparable
methodologies.25 This phase I-II clinical trial significantly improved median survival.25 A
follow-up study then demonstrated the role that the three-step protocol could play in adjuvant
treatment of high grade gliomas.26
Although the three-step protocol tended to outperform the two-step protocol, it’s
important to recognize that that is not always the case. It was found that high levels of rapid
antibody internalization, which occurs with streptavidinylated-MOv18 and streptavidinylated-
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MOv19 complexes, favored two-step protocols.11 Antibody complexes whose internalization is
promoted and mediated by cross-linking, e.g. streptavidinylated-FO23C5, found more favorable
outcomes using the three-step protocol.11
As noted earlier, immunogenic responses to avidin/streptavidin are a major concern. The
increase in human anti-streptavidin antibody found after treatment can lead to dangerous allergic
reactions to further treatment and has been attributed to the loss of interest in this system, in
favor of pretargeting strategies with fewer potential side-effects and increased potential for
repeated treatment, where clinically appropriate.2, 18, 27-28

1.3. Complementary Oligonucleotides
The next pretargeting strategy makes use of complementary oligonucleotides that
hybridize in vivo (Figure 4). Native phosphodiester DNAs are vulnerable to degradation by
nucleases and therefore are of limited use.29-31 The earliest oligonucleotide pretargeting efforts
used a DNA synthesizer to create 15-mers complementary oligodeoxynucleotides wherein the
5’-end was derivatized for labeling with radioactive iodine (125I) and the 3’ end was
functionalized for attachment to a MAb.29-30 The terminal modifications were chosen to not only
facilitate connection to the necessary pretargeting components (i.e. the radioisotope and MAb)
but also to protect against exonucleases in vivo.29-30 This seems to have been successful because
the stability of the modified oligonucleotides in human plasma (37°C) increased from 24 hours
for the unmodified versions to several days.29 Despite this modicum of protection, subsequent
work has circumvented nuclease degradation altogether by using peptide nucleic acids (PNAs)
and phosphorodiamidate morpholino oligomers (MORFs).
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Figure 4: Pretargeting with MAb with oligonucleotide and radiolabeled complementary oligonucleotide.

PNA is an oligonucleotide that retains DNA nucleobases but replaces the DNA
phosphodiester backbone with a pseudo-peptide backbone and was designed to recognize double
stranded DNA via Hoogsteen base pairing.32-33 As non-natural nucleic acid analogues, PNAs
hybridize with complementary strands quickly and effectively while remaining highly stable in
vivo and resisting degradation by nucleases/proteases.34-35 Although PNA pretargeting has not
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progressed to the clinic, a number of promising preclinical studies have shown the potential of
this strategy.
In one such study, an azido derivative of 2,2’-dipicolylamine (Dpa) labeled with 99mTc
and the cold Re analog was coupled with PNA and tested for in vivo properties.34 The
radiocomplex, [99mTc(CO)3(Dpa-PNA)], showed favorable characteristics, including relatively
high hydrophilicity (log Doctanol/water = -0.85 at pH = 7.4), fast blood clearance (0.26 ± 0.1 SUV, 1
hour post-injection), and high in vivo stability indicated by low uptake in the thyroid and
stomach in Wister rats.34 In a more recent study, two complementary 15-mer PNA strands, HP1
and HP2, were tested as pretargeting components for HER2-expressing cells.36 HP1 was
attached to an anti-HER2 Affibody to form the chimera ZHER2:342-SR-HP1, while HP2 was
functionalized with a DOTA chelator and tyrosine for labeling with 125I and 111In.36 Subsequent
tests in BALB/C nu/nu mice with xenografted SKOV-3 (an ovarian cancer cell line) tumors were
successful with 19 ± 2 %ID/g in the tumors 1 hour post-injection, 50 times higher than the
activity found in the blood and two times higher than the activity found in the kidneys.37 This last
point is particularly important given that high kidney uptake is a common concern associated
with affibody-based therapies.38-40
Another group optimized PNA oligomer pretargeting methods through PEGylation,
lowering kidney and liver accumulation while promoting renal clearance.41 The investigators
pretargeted A431 epidermoid carcinoma xenografted in NMRI nu/nu mice with 17-mer PNA
strands attached to epidermal growth factor receptor (EGFR) specific MAbs (cetuximab).41 After
24 hours, the animals were treated with radiolabeled complementary PNAs. Notably, the
investigators not only varied the PNA constructs through PEGylation, but also radiolabeled with
both 99mTc and 64Cu. With the positive results that they presented, their stated goal of testing this
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system using therapeutic radionuclides (90Y, 177Lu, 186Re, 188Re, etc…) should be followed
closely.
Although the following study was performed years earlier than those just described, its
novel approach to amplifying the benefits of pretargeting make it stand out.42 A 80 kDa
poly(methyl vinyl ether-alt-maleic acid) polymer (PA) was modified with ~200 PEGs (in order
to increase aqueous solubility) and then modified with ~80 PAN strands. The PNA-PA-PEG
polymer accumulated, through nonspecific diffusion, in xenografted tumors in mice and the
subsequent administration of 99mTc radiolabeled complementary PNA strands demonstrated that
amplification efforts can further improve localization for certain pretargeting strategies.
The Hnatowich Laboratory has been performing extensive pretargeting studies with
MORFs for over a decade and a half. As synthetic DNA analogs comprised of DNA bases
attached to phosphorodiamidate linked methylenemorpholine rings, MORFs exhibit many of the
same properties that make PNAs attractive, i.e. stable to nucleases and highly specific to
complementary strands.43 An early study showed that 99mTc labeled MAG3-MORFs (15 and 18
mer) had rapid pharmacokinetics and could effectively hybridize with complementary strands in
vivo.44 Soon after, mice with xenografted human colon cancer, LS174T cell line, were
pretargeted with MORF-MAb, murine anti-CEA antibody MN14, and 99mTc-MAG3-cMORF.45-46
Despite relatively high kidney uptake, the tumors were successfully imaged and all other nontarget tissues showed minimal uptake.45-46 Before moving forward, the laboratory investigated
the source of the higher than expected kidney uptake. It was established that MORFs rich in
cytosine favored accumulation in the kidney and that choosing cytosine-free 99mTc-MAG3cMORFs significantly improved tumor to kidney ratios.47-48
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The pretargeting conditions were then optimized using 99mTc before the cytosine-free
cMORF was radiolabeled with 111In, 90Y, and 188Re in preparation of therapeutic studies.49-52 A
subsequent preclinical study wherein LS174T tumor-bearing mice were pretargeted with MORFMAb, anti-TAG-72 CC49 antibody, and then treated with 188Re-MAG3-cMORF (maximum dose
of 1.40 mCi) found that this combination acted as an effective radiotherapeutic strategy.53 These
results were mirrored with 90Y-cMORF soon after.54 Even though these are preliminary studies,
they show the promise that MORF/cMORF pretargeting could have in the clinic.
While exploring this pretargeting system, there were several interesting details that
emerged beyond the efficacy of the system in and of itself. For one, the investigators compared
the maximum percent tumor accumulation for three MORF-conjugated antibodies (MN14,
B72.3, and CC49).55 They found that the maximum percent tumor accumulation of the
radiolabeled effector was independent of the antibody used for LS174T tumors and that
optimization of this parameter must be achieved through dosage (of both the MAb and
radiolabeled components) and timing.31, 55-56 Although antibody characteristics remain important
for maximum absolute tumor accumulation and tumor to non-target ratios, this study prevented
the need for additional optimization experiments in this tumor model.55 Another study
highlighted the effect that the radiolabel can have on pretargeting biodistributions. It was
determined that 99mTc-cMORF had significantly higher intestinal uptake than did 111In-cMORF,
despite comparable tumor uptake.57 Looking beyond the radiolabel, they also found that the
addition of a clearing agent reduces uptake in blood and normal tissues but does not reduce
tumor uptake.58 Lastly, they determined that the maximum percent tumor accumulation of both
the MAb and radiolabeled effector were not affected by the size of the tumor.59 While it is
important to avoid assuming that these results can be extended beyond LS174T tumors and
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MORF/cMORF pretargeting, they provide food for thought for pretargeting in general and
display the thoroughness and novelty of the work conducted by the Hnatowich Laboratory.

1.4. Bispecific Antibodies

Both strategies discussed so far function by modifying intact MAbs with a targetable
moiety. An alternative approach is possible using bispecific monoclonal antibodies (bsMAbs),
engineered proteins capable of binding two distinct targets. bsMAbs have been particularly
helpful in immunotherapy where they are commonly used to recruit T cells to tumor sites, but
they have been considered for use in pretargeting for decades.4, 60 Although bsMAbs can be
generated in a number of formats, i.e. comprised of various components to form immunoglobulin
G (IgG)-like or non-IgG-like molecules, pretargeting efforts have focused on combining various
Fab region fragments and single-chain variable fragments (scFvs).4, 60 The work has moved from
anti-tumor Fab’ x anti-chelate-metal Fab’ fragments (1st generation) (Figure 5) to anti-tumor Fab’
x anti-chelate-metal Fab’ fragments with divalent radiolabeled hapten-peptides (2nd generation)
(Figure 6) to anti-tumor F(ab’)2 x anti-HSG Fab with radiolabeled HSG peptides (3rd generation)
(Figure 7).2, 4
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Figure 5: Pretargeting with anti-tumor Fab’ x anti-chelate-metal Fab’ fragments and radiolabeled hapten.
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Figure 6: Pretargeting with anti-tumor Fab’ x anti-chelate-metal Fab’ fragments with divalent
radiolabeled hapten-peptides.
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Figure 7: Pretargeting with anti-tumor F(ab’)2 x anti-HSG Fab with radiolabeled HSG peptides.

The first clinical investigation into bsMAb pretargeting used the Fab’ fragments of ZCE025, an anti-CEA MAb, and CHA-255, an anti-metal chelate MAb.61 These components were
chemically linked to form the bsMAb F(ab’)2 which was then injected into 14 patients with
recurrent or metastatic colorectal edenocarcinoma.61 This construct was allowed to localize at the
tumor sites for four days before injection with an 111In chelate hapten.61 Despite the successful
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imaging of hepatic metastatic “hot” spots, the rapid release of the 111In chelate from the tumor
sites indicated a need for adjustments to the strategy.61-63
To improve affinity for the target, and thereby improve retention, it was suggested that
the radiolabeled chelate hapten could be engineered in such a way that it crosslinks two
pretargeted bsMAbs.63 The efficacy of this “affinity enhancement system” (AES) was soon
demonstrated in vivo when divalent haptens were successfully crosslinked on anti-dinitrophenyl
(DNP) bsMAb pretargeted on spleen lymphocytes in mice.64 The F(ab’)2 bsMAb was developed
by combining CY34, an anti-Lyb8.2 mouse MAb, with U7.27, an anti-dinitrophenyl (DNP)
mouse MAb.64 After administration of the resulting bsMAb, the animals were injected with
either a monovalent or divalent DNP derivatized peptide labeled with either 125I or 111In.64
Importantly, the divalent haptens outperformed the monovalent haptens and provided early
justification for continuing investigations into the AES. Furthermore, it was found that the
bivalent haptens had higher affinity for cell-bound bsMAbs than circulating bsMAbs, reducing
the need for administration of a clearing agent as an intermediate step.64
Taking the work further, the same group tested AES pretargeting in mice xenografted
with A375 (human melanoma) tumors.65 Pretargeting with the F(ab’)2 bsMAbs and 111In labeled
divalent haptens resulted in lower tumor localization but significantly improved
tumor:background ratios compared to a directly labeled 111In F(ab’)2.65 The 111In labeled divalent
hapten also showed higher targeting efficiency than its monovalent correlate both in vitro and in
vivo.65 An interesting follow-up study demonstrated that these benefits can be further enhanced
for cells that exhibit two targetable cell-surface antigens.66 In such cases, each antigen can be
targeted with a separate bsMAb, after which an asymmetric radiolabeled bivalent hapten, which
contains a single domain to target each bsMAb, will only crosslink cells that are positive for both
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antigens.66 Because this strategy relies on cells having two readily targetable antigens, it
exemplifies the potential for personalized pretargeting efforts that could provide additional
benefits beyond more generalized methods.
Moving into the clinic, the AES was shown to be more selective for primary colon
carcinoma in 11 patients pretargeted with anti-CEA x anti-DTPA bsMAbs and imaged with
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labeled divalent DTPA dimer than the non-AES, in which six patients were imaged with antiCEA F(ab’)2 MAbs directly labeled with 111In.67-68 Years later, another group used the same
bsMAb/111In labeled divalent DTPA dimer combination to image 44 patients with medullary
thyroid carcinoma.69 The patients were chosen after elevated levels of circulating calcitonin were
found following surgical removal of the primary tumor, indicating the potential presence of
metastases.69 A number of previously unknown metastases were, in fact, discovered and the AES
pretargeting aided in most of the resulting radioimmunoguided surgeries.69
Looking beyond imaging, mice xenografted with TT medullary thyroid cancer and
treated with 131I labeled divalent DTPA pretargeted with anti-CEA x anti-DTPA F(ab’)2 bsMAb
showed comparable tumor uptake and reduced non-target toxicity than the directly radiolabeled
counterpart.70 This translated to a high absorbed dose in small medullary thyroid cancer and
small cell lung cancer in a preliminary trial in humans, highlighting the potential
radioimmunotherapeutic benefits of AES in treating micrometasteses.70
Despite the notable success of AES, it is an inflexible system in that the bsMAbs must be
specifically designed to interact with a single chelate complex. A more modular system in which
radiometals can be easily interchanged to match various clinical conditions and optimize
outcomes is highly desirable.2, 4 The first key movement in this direction occurred when one
group designed a group of 125I labeled peptides with bivalent histamine-succinyl-glycine (HSG)
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haptens to be used in conjunction with an anti-CEA x anti-HSG bsMAb in in vivo pretargeting of
xenografted LS174T tumors.71 A similar system was then used with 111In to successfully
pretarget small cell lung cancer in mice.72 The breakthrough that ushered in the 3rd generation of
bispecific pretargeting came a few years later, however, when Sharkey et al. showed that the
HSG-labeled peptide could be modified to not only affect the pharmacokinetics and clearance of
the hapten complex but to also allow a wide range of SPECT (99mTc, 111In, etc.), PET (124I, 68Ga,
18

F, etc.), and therapeutic radioisotopes (131I, 90Y, 177Lu, etc.).73-75
While flexibility afforded by the diHSG-peptides was the most important innovation, the

system was further improved using trivalent bsMAbs comprised of two tumor binding Fabs and
one HSG binding Fab. Multiple studies demonstrated the in vivo efficacy of pretargeting with
trivalent bsMAbs, but the methods used to create these constructs slowed development.4, 76-78
This difficulty was finally circumvented through the use of dock-and-lock technology, wherein
an anti-tumor Fab links to another anti-tumor Fab with the aid of a dimerization and docking
domain, an anti-hapten Fab links to an anchoring domain, and then all three Fabs are secured
through disulfide bridges.79-81 Dock-and-lock facilitated the creation of additional trivalent
bsMAbs, which were all found to be effective in in vivo pretargeting with multiple tumor
systems; the most commonly used bsMAb moving forward was TF2, which is divalent for antiCEA and monovalent for HSG.82-87
Mice with LS174T xenografted tumors were pretargeted with TF2 followed by a 68Ga
labeled diHSG-peptide and the resulting images and tissue uptake were compared with that of
18

F-FDG, the gold standard in PET imaging.88-89 Although the 18F-FDG provided clear images of

the lesions, the 68Ga images were obtained with lower background in non-target tissues, showing
the desired increase in specificity associated with pretargeting strategies.88-89 These promising
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results prompted a first-in-human imaging trial a few years later. Five groups of three patients
were given variable amounts of TF2 followed by 68Ga labeled diHSG-peptide after a variable
interval.90 This study was able to determine the optimal pretargeting conditions, i.e. a
bsMAb:peptide mole ratio of 20 and a 30 hour interval, in which high tumor uptake and image
contrast was obtained.90
TF2 was also found to be effective in radioimmunotherapy studies in mice using 177Lu
labeled diHSG-peptide. The first found limited evidence of non-target toxicity while the second
used pretargeted 111In immune-SPECT to confirm tumor targeting and track and image the
delayed tumor growth.91-92 In both cases, survival was prolonged significantly.91-92 177Lu labeled
diHSG-peptide with TF2 was also tested in a phase 1 clinical trial. The trial was able to establish
that the pretargeting regimen was safe and that metastatic colorectal cancer can be rapidly and
specifically targeted in humans.93 Clearly, advances made in pretargeting with bsMAbs have
increased its clinical potential.

1.5. Bioorthogonal “Click” Chemistry
The final strategy, pretargeting using bioorthogonal “click” chemistry, harkens back to
the first two discussed in that it relies on modifying MAbs with pretargeting moieties, as opposed
to engineering bsMAbs. This strategy is younger than the others, with the most promising work
only emerging in the last decade, and was selected for use in the original research presented in
the rest of this paper. Before introducing the inverse electron-demand Diels-Alder (IEDDA)
reaction that paved the way for recent advances in in vivo pretargeting, it is worth developing an
understanding of bioorthogonal chemistry in general.
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To successfully probe cellular and biochemical processes in vivo a compound needs to 1)
have no interference or cross-reactivity with naturally occurring moieties (i.e. be bioorthoganol),
2) be reactive under physiological conditions, 3) be nontoxic, and (if applicable) 4) have a
minimal effect on the function of any biomolecules that is covalently attached to.94 Many early
bioconjugation methods made use of thiol-meleimide chemistry or amine-activated ester
conjugation.94 Despite being successful in vitro, they were not selective enough for in vivo use.94
The Staudinger ligation, wherein an azide reacts with a triaryl-phosphine to form an amide bond,
has high selectivity and was an improvement, but was too slow (rate constant = 0.0020 M-1 s-1)
for most in vivo applications.94-97 As the search for sufficiently fast bioorthogonal reactions
continued, the strain-promoted azide-alkyne cycloaddition (SPAAC) , a copper-free variant of
the copper(I)-catalyzed Huisgen azide-alkyne cycloaddition (a classic “click” reaction), was
discovered.98-100 Early versions of this reaction had rate constants comparable to that of the
Staudinger ligation but modifications to the system improved the rate constant by orders of
magnitude.101 This led to a number of successful cyclooctyne reagents being used to label azidemodified biomolecules both in vitro and in vivo (in live Caenorhabditis elegans, zebrafish, and
mice), but remained too slow for effective in vivo pretargeted imaging or therapy.95, 102 Building
off SPAAC, strain-promoted alkyne-nitrone cycloadditions (SPANC) achieved rate constants as
high as 60 M-1 s-1 and found use in protein and cell surface labeling.101, 103 This comparatively
fast reaction could not compare with the one reaction that would end up making in vivo
pretargeting with bioorthogonal chemistry not only feasible but also an attractive alternative to
the previously discussed strategies, however.
This innovative reaction was the inverse electron demand Diels-Alder (IEDDA) [4+2]
cycloaddition of 1,2,4,5-tetrazines (Tz) and trans-cyclooctene (TCO). First developed in 2008 by
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Blackman, Royzen, and Fox, the IEDDA reaction was bioorthogonal and exceptionally fast (rate
constant = 2000 M-1 s-1).104 The syntheses of the IEDDA reactants were quickly optimized and
the reaction was shown to effectively pretarget and image live tumor cells in vitro.105-108 In 2010,
Rossin et al. injected LS174T tumor-bearing mice with CC49 MAbs modified with TCO (CC49TCO) followed 24 hours later by an 111In labeled Tz.109 Importantly, the resulting SPECT/CT
images and biodistributions revealed that this in vivo pretargeting strategy was highly effective,
which led to a considerable number of imaging and/or therapy studies in mice using various
radioisotope-chelate complexes modified with Tz and targeting vectors modified with TCOs.
Although only some of these systems had favorable enough pharmacokinetic and clearance
properties to indicate potential for translation to the clinic, they all confirmed the Tz-TCO
“click” reaction in vivo and cemented bioorthogonal “click” chemistry’s place as a viable
pretargeting strategy (Figure 8). To organize the discussion of these in vivo IEDDA studies,
systems targeting specific xenografted tumor types will be explored separately followed by those
with non-tumor targets.
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Figure 8: Pretargeting with TCO-MAb and radiolabeled-Tz.

Quickly following the in vivo success of Rossin et al., Zeglis et al. pretargeted SW1222
colorectal cancer xenografts with huA33, a humanized MAb that targets a transmembrane
glycoprotein (A33 antigen) found in 95% of human colorectal cancers and has a slow cellular
internalization rate, modified with TCO (A33-TCO).110-112 After allowing the A33-TCO to
accumulate for 24 hours, they injected 64Cu-NOTA-Tz and performed biodistributions and PET
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imaging.112 Not only did the images clearly differentiate the tumors, but the biodistributions
showcased the benefits of pretargeting. The activity was well-retained in the tumor (4.1 ± 0.3
%ID/g 12 hours post-injection) and although the total tumor uptake was lower than what was
observed for A33 directly labeled with 64Cu and 89Zr, the dose to non-target tissues was
significantly lower.112 Adapting this success for PRIT, SW1222 tumor-bearing mice were
pretargeted with A33-TCO and then treated with 177Lu-DOTA-PEG7-Tz.113 24 hours after
treatment, 21.2 %ID/g ± 2.9 was retained on the tumor with low uptake in non-target tissues.113
Improvements in survival, reductions in tumor volume, and favorable dosimetric profiles
combined to show the high degree of promise that this treatment strategy could make its way into
the clinic.
Using the same type of xenografted tumors used in the seminal Rossin et al. study
(LS174T), Devaraj et al. confirmed the IEDDA in vivo “click” reaction using A33-TCO and 18F
labeled polymer modified Tz.114 Garcia et al. also confirmed the in vivo “click” on LS174T using
CC49-TCO and 99mTc-HYNIC-Tz, but unfavorable clearance (high uptake and retention in the
large intestines, kidneys, and liver) suggested that alternative, more hydrophilic 99mTz complexes
would need to be investigated.115 Another group had more luck pretargeting LS174T tumorbearing mice with AVP04-07 diabodies modified with TCO and 177Lu-DOTA-Tz.116 The
investigators observed relatively high tumor uptake (6.9 %ID/g) with a tumor:kidney ratio of
6:1.116 The low renal uptake is important given the propensity of diabodies to be retained in the
kidneys.116 Although these results are less striking than those seen in the more comprehensive
study performed later by Membreno et al., they highlight the potential for PRIT with
bioorthogonal “click” chemistry in a different tumor system.113
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The next xenografted tumor system that has been studied with IEDDA pretargeting is
BxPC3, a human pancreatic cancer cell line. In the first study, the tumor-bearing mice were
pretargeted with 5B1, an anti-CA19.9 MAb, modified with TCO and imaged with
Al[18F]NOTA-PEG11Tz.117 The tumors were clearly visualized with PET and 6.4 %ID/g
remained in the tumor four hours post-injection.117 Additionally, the effective dose was 60 times
lower than that of directly labeled 89Zr-DFO-5B1.117 A year later, a PRIT study with 5B1-TCO
and 177Lu-DOTA-PEG7-Tz found rapid (4.6 ± 0.8 %ID/g four hours post-injection) and
persistent (16.8 ± 3.9 %ID/g 120 hours post-injection) tumor uptake along with fast blood
clearance, minimal nontarget uptake, and favorable dosimetry.118
The final tumor system used HER2-expressing SKOV-3 ovarian cancer xenografts and
pretargeted with anti-human epidermal growth factor receptor 2 (HER2) affibody molecule Z2395
modified with TCO.119 The in vivo “click” was confirmed for both 177Lu-DOTA-PEG10-Tz and
111

In-DOTA-PEG10-Tz and the 111In pretargeting led to a 56-fold decrease in renal uptake

compared to affibodies directly labeled with 111In.119 Once again, this is notable given the
propensity of affibody molecules to be absorbed and retained in the kidneys, which are
particularly sensitive to damage from radioactive dose.
The last set of studies used IEDDA “click” reactions to pretarget non-tumor targets. The
first allowed TCO-modified silica nanoparticles to passively accumulate in mouse lungs before
injecting a 11C labeled Tz.120 The lungs should a marked increase in %ID/g, which was supported
with PET imaging.120 Although these results were less exciting in and of themselves when
compared with some of the imaging studies already discussed, the addition of a 11C-Tz to the
chemical tool kit is noteworthy.
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The next two studies modified bisphosphonate with TCO (BP-TCO) to target regions of
active calcium metabolism and confirm the in vivo IEDDA “click.” The first confirmed the
“click” with both a 99mTc and 177Lu labeled Tz, which was retained in the knees and shoulders
with pretargeting but not observed in the skeleton and joints when administered without the BPTCO.121 The second confirmed the “click” between 99mTc-HYNIC-Tz and BP-TCO but then
went on to use the same radiolabeled complex to successfully image Staphylococcus aureus
infections pretargeted with a TCO modified vancomycin derivative.122
Although there has been considerable progress in in vivo pretargeting with bioorthogonal
IEDDA “click” chemistry, optimization efforts are on-going. The most comprehensive study was
performed by Meyer et al. wherein optimal structural characteristics of radioligands were
investigated.123 The parameters investigated included various forms of Tz, linkers (PEGn and/or
K, H, R, or D amino acids), chelators, and radiometals (18F and 68Ga) and the corresponding
effects on serum stability, log D, plasma half-life, and molecular charge.123 Biodistributions and
PET imaging were also performed in order to confirm which combinations provided the best in
vivo characteristics.123 Notable findings from this paper included: 1) a significant negative
correlation between Log D values and overall molecular charge was found; 2) complexes with
larger overall molecular charges cleared more quickly by renal excretion; 3) complexes with
larger numbers of formally charged components demonstrated more negative Log D values than
those with the same molecular charge but fewer formally charged components; 4) the lead 18F
complex, [18F]27, had a net charge of 0 and a Log D of -1.34±0.18; 5) the lead 68Ga complex,
[68Ga]27, had a net charge of +1 and a Log D of -1.45±0.12; and 6) the lead complexes (by
definition) achieved the highest target to non-target ratio.
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An earlier study by Rossin et al. determined that linking a TCO-acetamide derivative to a
CC49 MAb showed better pharmacokinetic and clearance properties than a CC49 MAb linked
with a TCO-benzamide.124 The new, more hydrophilic, TCO improved CC49-TCO circulation
times, improved tumor uptake 1.5-fold, and improved in vivo stability 2.6 fold, despite a 2-fold
lower reactivity towards Tz.124 More investigations of the effect of the TCO linker have
produced mixed results. One group used a fluorescent-Tz to test the efficacy of targeting MAbPEGn-TCO in vivo.125 Those authors found that using no PEG linker was preferable to using
PEG4 or PEG12 linkers and postulated that while PEGn could improve the accessibility of TCO to
Tz, it decreased the total number of reactive TCO per MAb.125 This finding conflicted with an
earlier study that found that the improved accessibility afforded by TCO PEGylation led to a
greater than 5-fold enhancement in functional density and increased the number of Tz that could
react with a given MAb.126 Circumventing this question altogether, Cook, Membreno, and
Zeglis used a dendrimer scaffold (DEN) to increase the number of TCO moieties per MAb from
~2 to ~8.127 This strategy more than doubled tumor uptake of [64Cu]Cu-SarAr-Tz pretargeted
with A33-DEN-TCO (8.9 ± 1.9 %ID/g) over the same radio-complex pretargeted with A33PEG12-TCO.127
In an attempt to further improve pretargeting with IEDDA chemistry, Rossin et al.
developed two Tz-functionalized clearing agents to remove circulating CC49-TCO.128 These
agents helped optimize 177Lu labeled-Tz treatment of LS174T tumor-bearing mice and
significantly improved the uptake of Tz on the tumor while decreasing the tumor:blood ratio.128
More recently, Meyer et al. developed a Tz-modified dextran polymer (DP-Tz) that can scavenge
circulating MAb-TCO without decreasing tumor uptake.129 The strategy, called “bioorthogonal
masking,” significantly improved tumor:blood ratios for [68Ga]Ga-NOTA-PEG11-Tz with 5B1-
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TCO and xenografted BxPC3, as well as A33-TCO and xenografted SW1222.129 Importantly, the
clearing agent was found to be nontoxic and nonimmunogenic, indicating potential for clinical
translation.129 The improved tumor delineation, enhanced PET image quality, and reduced nontarget uptake clearly justified these efforts.129
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Chapter 2
Research Project Introduction
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2.1. Introduction: 99mTc and 188/186Re
As indicated by the efforts of multiple groups, technetium-99m is an obvious choice to
leverage the benefits of and recent developments in pretargeting. This is because 99mTc is a
ubiquitous imaging agent that accounts for over 80% of global radiopharmaceutical medical
imaging and has extremely favorable physical characteristics for SPECT.130 Its relatively short
half-life (t1/2 = 6.0058 hours) means that it causes lower internal radiation dose to patients,
thereby allowing for a high limit of injectable activity and improved images. Additionally, its
140 keV photon (emitted with 89% abundance) is easily detectable and has been found to be
optimal for diagnostic applications in nuclear medicine.131 Lastly, it is comparatively
inexpensive and widely available; 99Mo/99mTc generators are commercially available and can be
shipped where needed, even to remote regions.131
99m

Tc is also attractive because it is in the same transition metal group as 188Re and 186Re,

which both have potential applications as radiotherapeutics.132 188Re can be obtained from a
generator (188W/188Re) and is relatively inexpensive.131 It has a high-energy 𝛽-emission (2.12
MeV) with a 17.0 hour half-life, allowing for potentially high dose rates and repeated
administration for radiotherapy.131 Additionally, with a 155 keV γ-emission (15% abundance),
188

Re can be tracked in vivo and act as a theranostic agent.132 186Re shares this theranostic

potential, with moderate energy 𝛽-emissions (1.07 and 0.933 MeV) and a low-abundance (9%)
γ-emission.131 Although 186Re is reactor-produced and not available via a generator, its longer
half-life (3.7 days) allows transport for potential use as a radiopharmaceutical.132
Technetium and rhenium have similar physico-chemical and chemical properties,
allowing many chelators to function effectively for either metal. In fact, . non-radioactive
(“cold”) macroscopic rhenium is commonly used as an analog to characterize 99mTc complexes
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because there are no non-radioactive technetium isotopes. This is all to say that knowledge and
expertise gained with 99mTc has the potential to be translated to 186Re and 188Re, allowing
pretargeted radiotherapy in addition to imaging. With this in mind, the overall goal of the
research undertaken for this dissertation was to develop a viable 99mTc imaging agent that can
make use of biorthogonal Diels-Alder “click” chemistry for pretargeted SPECT imaging.
The 99mTc imaging agent is considered viable if it is isolatable, can react in vivo with
modified antibodies, and produces a high tumor-to-background ratio. To accomplish this goal a
method was developed to complex the ligand with 99mTc while maintaining the integrity of the
“clickable moiety,” i.e. the Tz. The resulting complex must have favorable clearance, avoiding
large uptake in the gut and intestines while maintaining a long enough blood half-life to
accommodate the “click” reaction on the tumor. To characterize the tracer 99mTc imaging agent,
cold (i.e. non-radiactive) Re analog complexes must be developed and analyzed.
In order to satisfy these requirements, a peptide-based chelator backbone was chosen to
complex with 99mTc and subsequently be appended with a Tz moiety. This decision was made in
the context of a long history of 99mTc-labeled peptides and their derivatives being tested and used
in nuclear medicine. Before providing additional details on the specific ligand system used in
this work, it is important to discuss this history and more fully explore the relevant chemistries of
both Tc and Re.

2.2. 99mTc and 188/186Re peptide complexes
As a group 7 transition metal on the periodic table, technetium (Tc) has an electron
configuration of [Kr]4d55s2. Consequently, Tc can accommodate a diverse ligand environment.
In oxidizing conditions, Tc tends to remain in the +7 oxidation state in the form of pertechnetate
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(TcO4-).132 When 99mTc is eluted from 99Mo/99mTc generators as Na99mTcO4, it must be reduced
to achieve the +1, +3, +4, or +5 oxidation states most frequently used in
radiopharmaceuticals.133-140 In general, an appropriate reducing agent (e.g. Sn2+) is reacted with
99m

TcO4- in the presence of a coordinating ligand, which stabilizes the 99mTc in a lower oxidation

state.132 Reaction conditions tend to be mild and radiopharmaceutical kits are often prepared for
clinical use, wherein freshly eluted 99mTcO4- can be added to pre-manufactured mixtures of
reducing agents, ligands, and any additional stabilizing and/or catalyzing agents.132 These
reactions are optimized and tend to yield products with >95% radiochemical purity.132 Due to its
similar chemistry, 186/188ReO4- can be reduced in the presence of ligands to form
radiopharmaceuticals in much the same way as 99mTcO4- can.132 Rhenium has a lower redoxpotential than Tc, however, requiring approximately two to three orders of magnitude more
reducing agent than is needed for Tc.131, 141 Furthermore, Re tends to have slower reaction
kinetics than Tc and requires a lower pH to prevent back-oxidation to ReO4-.52
Following the development of 111In-DTPA-Octreotide (OctreoScan) for the diagnosis of
somatostatine (SST) receptor-positive tumors in 1994, interest in developing novel peptide-based
imaging agents for thrombosis, infection, inflammation, and cancer accelerated.131 This is not
only because peptide-based imaging agents have the potential to target overexpressed receptors
(e.g. SST, bombesin, and α-melanocyte), but also because they are relatively easy to synthesize
and modify (allowing for tunable pharmacokinetics) and have low immunogenicity and
toxicity.131 Additionally, peptides are more robust than larger proteins (e.g. antibodies) and are
better able to withstand harsher reaction conditions (an important consideration for the synthesis
of 186/188Re complexes).
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The first 99mTc peptide-based radiopharmaceutical approved for use in the clinic was
[99mTcO] apcitide for imaging thrombosis. Apcitide is a 13 amino acid peptide (cyclo-[D-TyrApc-GlyAsp-Cys]-Gly-Gly-Cys(Acm)-Gly-Cys(Acm)-Gly-Gly-Cys-NH2) that binds to platelet
glycoprotein receptors (GPIIb/IIIa) (C5).142 The 99mTc is bound by the three amide nitrogens and
one sulfur in the C-terminal Gly-Gly-Cys segment of apcitide as an N3S complex.143 The second
99m

Tc peptide-based radiopharmaceutical approved by the FDA was [99mTcO]depreotide, which,

much like 111In-DTPA-Octreotide, contains an SST receptor binding sequence and was used in
the diagnosis of SST receptor-positive tumors (e.g. non-small cell lung cancer).144 It also
contains a linear tetrapeptide sequence wherein the 99mTc again forms an N3S complex.
Additional 99mTc SST-binding complexes have been tested preclinically (e.g. 99mTc-Demotate
and 99mTc-Mag3-RC-160), but have not advanced into the clinic.145-146 Adding to these, a few
188

Re complexes have been developed for potential use as radiotherapeutics. This includes

[188ReO]depreotide, which was designed with a full kit formulation, and 188Re-RC-160 and
188

Re-P2045, both of which showed preclinical tumor suppression efficacy in mouse models.147-

149

Beyond SST, attention has been paid to developing bombesin (BBS)/gastrin-releasing
peptide (GRP), alpha-melanocyte stimulating hormone (α-MSH), neurotensin (NT), and ArgGly-Asp (RGD) based complexes. Some of these, as well as a selection of additional peptidebased Re/Tc complexes, are included in Table 3.
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Compound

Reference
Van de Wiele, et al. 150

99m

Tc-RP-527

186/188

Re-N3S-5-Ava-BBS(7-14)NH2

188

Re-P2S2-5-Ava-BBS(7-14)NH2

188

Re-Dpr-SSS-BBS(7-14)

188

Re-(CO)3-labeled BBS(7-14)

Moustapha, et al. 151
Gali, et al. 152
Smith, et al. 153

99m

Smith, et al. 154; Smith,
et al. 155
Chen, et al. 156

99m

Chen, et al. 156

99m

Tc-CCMSH

Chen, et al. 157

188

Re-CCMSH

Miao, et al. 158

188

Re-(Arg11) CCMSH

Miao, et al. 159

188

Re-HYNIC-4B4

Tc-CGCG-α-MSH
Tc-MAG2-α-MSH

Dadachova, et al. 160

99m

Garcia-Garayoa, et al. 161

188

Blauenstein, et al. 162

Tc(CO)3-NT(8-13)

Re(CO)3-NT(XI, XII, XIX)

99m

Tc-RGDSCRGDSY

Sivolapenko, et al. 163

188

Re-RGDSCRGDSY

Costopoulos, et al. 164

99m

Guleria, et al. 165

99m

Yan, et al. 166

188

Gestin, et al. 167

Tc-[E-c(RGDfK)2]2
Tc-3P-RGD2

Re-MAG3-AG 8.0

168

Karacay, et al.
Re-IMP-192
Table 3: 186/188Re and 99mTc peptide-based radiocomplexes.

186/188

2.3. Research Project Overview
An N3S chelated 99mTc-tripeptide (99mTc-phenylalanine-lysine-cysteine-arginine [99mTcFKC]) and Re-tripeptide (Re-phenylalanine-lysine-cysteine-arginine [Re-FKC]) were previously
synthesized and characterized by this laboratory.169 This 99mTc tracer and its analog were chosen
for potential use as a pretargeted SPECT imaging agent due to the potential for reaction of the
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terminal amine of the lysine residue

and a N-hydroxysuccinimde ester on a Tz (Tz-NHS),

which is commercially available.
Early in vivo SPECT imaging with 99mTc-FK(Tz)C somewhat visualized the tumor
confirming the Tz-TCO reaction, but high intestinal uptake indicated that the complex was not
appropriate for use in the clinic. Consequently, alternative N3S 99mTc-peptide-Tz complexes were
tested, with the goal of improving the pharmacokinetic and clearance characteristics and
obtaining higher tumor:background ratios and clearer SPECT/CT images. Informed by the
optimization efforts of other groups, PEG linkers between the lysine and Tz were used and more
charged or polar amino acids were substituted or appended on the peptide chelator.123
The tri- and tetra-peptide complexes that were synthesized and compared to the baseline
characteristics of 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C were 99mTc(V)-phenylalaninelysine(tetrazine)-cysteine-arginine (99mTc-FK(Tz)CR;), 99mTc(V)-phenylalanine-lysine(PEG5tetrazine)-cysteine-arginine (99mTc-FK(PEG5-Tz)CR; Figure 1B), 99mTc(V)-aspartic acidlysine(tetrazine)-cysteine (99mTc-DK(Tz)C; Figure 1C), 99mTc(V)-aspartic acid-lysine(PEG5tetrazine)-cysteine (99mTc-DK(PEG5-Tz)C; Figure 1D), 99mTc(V)-serine-lysine(tetrazine)cysteine (99mTc-SK(Tz)C; Figure 1E), and 99mTc(V)-serine-lysine(PEG5-tetrazine)-cysteine
(99mTc-SK(PEG5-Tz)C; Figure 1F). All eight complexes were reacted with TCO modified
bovine serum albumin (BSA-TCO) to confirm the integrity of the Tz moieties. The Log P values
were then determined to confirm the desired increase in hydrophilicity of the six modified
complexes over the 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C. Based on this result, the three
most promising complexes, 99mTc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTcSK(PEG5-Tz)C, were selected for in vivo studies and compared against 99mTc-FK(Tz)C.

41

The biphasic blood half-lives were measured in addition to the biodistributions in healthy
athymic nude female mice. 99mTc-FK(PEG5-Tz)CR showed the greatest decrease in intestinal
uptake and had a blood half-life that was sufficiently long to accommodate an in vivo Tz-TCO
“click” reaction. These results indicated that 99mTc-FK(PEG5-Tz)CR was the lead complex for in
vivo imaging efforts and contributed to the decision to allocate more resources (e.g. more tumorbearing mice, additional characterization efforts for the Re analog) to its evaluation. However, all
four complexes (99mTc-FK(Tz)C, 99mTc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTcSK(PEG5-Tz)C) were used in SPECT/CT imaging of SW1222 tumor-bearing mice pretargeted
with A33-TCO. Biodistribution studies were also performed to determine the tumor:background
ratios.
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Figure 9: A. 99mTc-FK(Tz)CR B. 99mTc-FK(PEG5-Tz)CR
C. 99mTc-DK(Tz)C D. 99mTc-DK(PEG5-Tz)C
E. 99mTc-SK(Tz)C F. 99mTc-SK(PEG5-Tz)C
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Chapter 3
Synthesis and characterization of 99mTc-peptide
and 99mTc-peptide-tetrazine (Tz) constructs
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3.1. Introduction: Structure and bonding of 99mTc and Re peptides
The reaction of 99mTcO4- with Sn(II) in the presence of peptides comprised of L amino
acids forms square pyramidal d2 closed shell diamagnetic complexes, where the TcV=O moiety is
in the apical position with the N3S donor atoms as the base of the square pyramid.170-171 It should
be noted that the amide nitrogens (N2 and N3 in Figure 10) are deprotonated in the Tc/Re
complex and are counted as a -1 charge to the resulting complex.169 The amine nitrogen (N1) is
either protonated as shown in Figure 11 or deprotonated depending on the substituents.169 This
will influence the charge of the metal chelate and, thus, may have importance on the overall
pharmacokinetics of the 99mTc species.123 The species shown in Figure 11 would have a neutral
chelate charge (-1 for each amide N, -1 for the thiolate S and +3 for the MV=O group). These Tc
and Re complexes will be denoted using the single-letter amino acid code.
In addition, two diastereomers form: one in which the TcV=O moiety is “syn” to the
amino acid residues and the other in which the TcV=O moiety is “anti” to the amino acid
residues.172-177 This is shown in Figure 11. In previous work in this laboratory, it was shown that
the first peak to elute on an HPLC system consisting of a C18 column in acetonitrile/water (0.1%
TFA) mobile phase is the “anti” diastereomer and the second peak is the “syn” diastereomer
(Figure 12).169 Before spending resources to fully separate diastereomers of 99mTc-peptidetetrazine complexes, it is more important to tune the physical properties, such as hydrophilicity
and charges on the periphery, to confirm its clinical potential. Once a viable peptide construct is
built, the effects of the diastereomers on the biodistributions can be explored.
The Zeglis and Lewis laboratories have found that chelate charge can be a contributing
factor in pharmacokinetics of small molecule radiometal tetrazine complexes.123 As mentioned
above, this can be complicated in the case of peptide ligands. Through crystallography and NMR
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studies, previous members of this lab have found that the amine nitrogen can either be protonated
or deprotonated, i.e. forming a metal amide bond.169 This is illustrated in Figure 13 and Figure
14. The lysine residue on Re-FKC lowers the pKa of the amine proton so that under
physiological pH, one would expect mostly the amide species. This should be considered in the
design of the constructs and needs to be examined by synthesis of the macroscopic Re standard
to determine the pKas. However, it is possible to completely circumvent this by either: 1)
capping off the amine nitrogen with methyl groups that would result in an overall neutral charge
to the chelate or 2) by extending the amine terminus by one or two amino acids that would result
in an amide bound to the Tc/Re giving an overall negative charge to the chelate (not considering
any charged residues). In this study, we are writing the N1 as an amide consistent with the past
studies where the amide species is found under physiological pH.

Figure 10: The tripeptide chelated MV=O moeity (where M = 99mTc/Re) forms square pyramidal
d2 closed shell diamagnetic complexes. N1 and N2 are deprotonated while N1 may either be
protonated or deprotonated.169
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A

B

Figure 11: Two diastereomers formed from the tripeptide chelated MV=O (where M = Tc/Re).
A is “syn” to the amino acid residues and B is “anti” to the amino acid residues.169

Figure 12: The first peak to elute on an HPLC system consisting of a C18 column in
acetonitrile/water (0.1% TFA) mobile phase is the “anti” diastereomer (A) and the second peak
is the “syn” diastereomer (B).169
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Figure 13: The amine nitrogen of the tripeptide chelated MV=O can either be protonated or
deprotonated, i.e. forming a metal amide bond.169

Figure 14: Equilibria between the Metal-Amine and the Metal-Amide form of [ReO]FKC.169

3.2. Materials
99m

Tc was obtained via Memorial Sloan Kettering Cancer Center, New York, New York,

as Na99mTcO4, eluted from a 99Mo/99mTc Generator. Activity measurements were obtained from
an Atomic Products Corporation Atomlab 100 Dose Calibrator. The ligands, FKC, FKCR, DKC,
and SKC, were purchased from ABclonal Science, Inc., dimethyl sulfoxide (DMSO), HPLCgrade acetonitrile, triflouroacetic acid (TFA), and 0.9% NaCl solution were purchased from
Fisher Scientific. Tin (II) tartrate 99%, tin (II) chloride dehydrate, and d- gluconic acid was
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purchased from Sigma Aldrich. Deionized water was obtained from a 0.22μm Millipore filtration
system. All in vivo experiments were performed according to protocols approved by the
Memorial Sloan-Kettering Institutional Animal Care and Use Committee.

3.3. Syntheses
3.3.1. Synthesis of 99mTc-FK(Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL FKC (2 mg/mL 0.9% saline), and 40 μL
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to
proceed for 10 minutes at 90°C. The product, 99mTc-FKC, was HPLC purified using a Waters
Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in
water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at a
retention time of 16.2-17.1 minutes and taken to dryness using a vacuum line. The product was
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product,
Tc-FK(Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical

99m

column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile
(solvent B) mobile phase. The product was collected at a retention time of 27.3-28.6 minutes and
taken to dryness using a vacuum line.

3.3.2. Synthesis of 99mTc-FK(PEG5-Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL FKC (2 mg/mL 0.9% saline), and 40 μL
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filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to
proceed for 10 minutes at 90°C. The product, 99mTc-FKC, was HPLC purified using a Waters
Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in
water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at a
retention time of 16.2-17.1 minutes and taken to dryness using a vacuum line. The product was
reconstituted in 300 μL DMSO. 10 μL Tz-PEG5- NHS (25 mg/mL in DMSO) and 5 μL DIEA
was added and the reaction was allowed to proceed for 30 minutes at room temperature. The
product, 99mTc-FK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 25.9-28.1
minutes and taken to dryness using a vacuum line.

3.3.3. Synthesis of 99mTc-FK(Tz)CR
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL FKCR (2 mg/mL 0.9% saline), and 40
μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed
to proceed for 10 minutes at 90°C. The product, 99mTc-FKCR, was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 17.5-18.9 minutes and taken to dryness using a vacuum line. The product was
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product,
Tc-FK(Tz)CR, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical

99m
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column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile
(solvent B) mobile phase. The product was collected at a retention time of 26.0-26.8 minutes and
taken to dryness using a vacuum line.

3.3.4. Synthesis of 99mTc-FK(PEG5-Tz)CR
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL FKCR (2 mg/mL 0.9% saline), and 40
μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed
to proceed for 10 minutes at 90°C. The product, 99mTc-FKCR, was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 16.5-17.8 minutes and taken to dryness using a vacuum line. The product was
reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product,
Tc-FK(PEG5-Tz)CR, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å

99m

analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 26.0-27.5
minutes and taken to dryness using a vacuum line.

3.3.5. Synthesis of 99mTc-DK(Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL DKC (2 mg/mL 0.9% saline), and 40 μL
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to
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proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line
and reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5 μL DIEA was
added and the reaction was allowed to proceed for 30 minutes at room temperature. The product,
Tc-DK(Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å analytical

99m

column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and acetonitrile
(solvent B) mobile phase. The product was collected at a retention time of 19.6-21.1 minutes and
taken to dryness using a vacuum line.

3.3.6. Synthesis of 99mTc-DK(PEG5-Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL DKC (2 mg/mL 0.9% saline), and 40 μL
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to
proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line
and reconstituted in 300 μL DMSO. 10 μL Tz-PEG5- NHS (25 mg/mL in DMSO) and 5 μL
DIEA was added and the reaction was allowed to proceed for 30 minutes at room temperature.
The product, 99mTc-DK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm
100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 20.0-22.3
minutes and taken to dryness using a vacuum line.

3.3.7. Synthesis of 99mTc-SK(Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe
filter. 565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL SKC (2 mg/mL 0.9% saline), and
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40 μL filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was
allowed to proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a
vacuum line and reconstituted in 300 μL DMSO. 10 μL Tz- NHS (25 mg/mL in DMSO) and 5
μL DIEA was added and the reaction was allowed to proceed for 30 minutes at room
temperature. The product, 99mTc-SK(Tz)C, was HPLC purified using a Waters Symmetry C18
3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent
A) and acetonitrile (solvent B) mobile phase. The product was collected at a retention time of
19.5-21.0 minutes and taken to dryness using a vacuum line.

3.3.8. Synthesis of 99mTc-SK(PEG5-Tz)C
A saturated aqueous solution of Sn (II) tartrate was filtered using a 0.1 μm syringe filter.
565 μL 99mTcO4- (80 mCi/565 μL 0.9% saline), 200 μL SKC (2 mg/mL 0.9% saline), and 40 μL
filtered Sn (II) tartrate were combined and vortexed for 2 minutes. The reaction was allowed to
proceed for 10 minutes at 90°C. The reaction mixture was taken to dryness using a vacuum line
and reconstituted in 300 μL DMSO. 10 μL Tz-PEG5-NHS (25 mg/mL in DMSO) and 5 μL
DIEA was added and the reaction was allowed to proceed for 30 minutes at room temperature.
The product, 99mTc-SK(PEG5-Tz)C, was HPLC purified using a Waters Symmetry C18 3.5 μm
100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 21.3-23.5
minutes and taken to dryness using a vacuum line.
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3.4. HPLC Analyses
All analytical and preparatory HPLC methods used during the syntheses of these
compounds were performed using a VARIAN ProStar UV-vis HPLC system interfaced with a
NaI detector and a Tennelec Minibin power supply, high voltage supply, and amplifier. All
HPLC experiments monitored the 99mTc γ emissions as well as the absorbance units at λ =
260nm. The mobile phase consisted of 0.1% trifluoroacetic acid in (A) H2O and (B) acetonitrile.
A Waters Symmetry C18 5μm 4.6x100mm column was used with various mobile phase gradients
(e.g. 5-45% B over 40 minutes).

3.5. Log P Analyses
To determine the partition coefficients the 99mTc complexes were dried via high vacuum
system following synthesis. The product was reconstituted in H2O and placed into a micro
centrifuge tube with an equal amount of 1-octanol. The samples were vortexed and then
centrifuged at 10,000 rpm for 5 minutes. Aliquots were taken from both layers and then counted
on a Perkin Elmer Automatic Wizard γ-counter. The logarithm of the ratio of the activity in the
1-octanol to the activity in the H2O was then calculated. This procedure was completed in
triplicate for each complex and the mean values and standard deviations were reported.

3.6. Radio-TLC Analyses
To avoid wasting huA33-TCO confirming the integrity of the tetrazine moiety for every
complex, BSA was modified with TCO. The degree of conjugation (TCO/BSA) was calculated
to be 0.833 by reacting BSA-TCO with Cy5-methyltetrazine and analyzing with UV-vis
spectroscopy. Could you give more details including a reference or two.
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To confirm the integrity of the tetrazine moiety in each 99mTc complex, the complex was
reconstituted in PBS following standard synthesis and high vacuum drying. This complex was
spotted on a silica gel TLC plate (mobile phase: 50% ACN, 50% H2O, 0.1% TFA) and analyzed
via radio-TLC. The remaining complex was reacted with BSA-TCO, spotted on a silica gel TLC
plate, and analyzed via radio-TLC. The reaction mixture was then run through a PD-10 size
exclusion column, spotted on a silica gel TLC plate, and analyzed via radio-TLC.

3.7. Results and Discussion
3.7.1. Synthesis and Isolation of 99mTc-peptide and 99mTc-peptide-Tz constructs
A series of related tri- and tetra-peptide-tetrazine-99mTc complexes were synthesized for
in vivo testing. This peptide motif was chosen because: 1) the N3S core forms stable technetium
complexes; 2) judicious choice of amino acids (natural and non-natural) and linkers (PEG and
others) may allow “tuning” of the pharmacokinetics to optimize tumor uptake and drive the
clearance through the kidneys which is desirable; 3) the lysine moieties and aspartic acid
moieties can be derivatized with appropriate tetrazine reagents; and 4) this research group has
knowledge of the chemistry, including stereochemistry, of Tc and Re complexes of N3S peptide
constructs.
The synthetic approach, detailed in the above experimental section involved: 1) synthesis
of the 99mTc peptide and purification via HPLC; 2) dry-down of the HPLC fraction to a film of
the 99mTc peptide; 3) reconstitution of the 99mTc peptide in DMSO and reaction with the
tetrazine-NHS ester with the lysine of the 99mTc peptide; 4) HPLC purification to collect the final
99m

Tc-peptide-tetrazine construct. This approach was used because of the concern that the Sn(II)

used to reduce 99mTcO4- would result in decomposition of the tetrazine. This approach involving
the first HPLC purification removed any excess Sn from the system.
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It was later determined that Sn(II) may not be as detrimental to the tetrazine moiety as we
originally thought and it was found that it is possible to eliminate the first HPLC purification (to
obtain the 99mTc peptide) and simply dry-down the reaction prior to reconstitution in DMSO and
reaction with tetrazine. This will be discussed in the synthesis of the new hydrophilic analogs.
Please note, while diastereomers almost certainly form (as discussed previously) for both
the 99mTc-peptide and 99mTc-peptide-tetrazine complexes, isolating a single 99mTc-peptidetetrazine diastereomer is not a priority. Upon reaction with tetrazine, the radioactive peak in the
HPLC that shifts upon addition of tetrazine was collected. This may be a mixture of both
diastereomers; however, at this point in the development of a preclinical imaging agent, it is
more important to obtain any 99mTc-peptide-tetrazine construct that may be useful. Once a viable
construct is identified with respect to pharmacokinetics, the diastereomeric structure can be
fleshed out. Therefore, the basic structure of the 99mTc-peptide-tetrazine constructs are
represented instead of the specific diastereomers.
99m

Tc-FK(Tz)CR and 99mTc-FK(PEG5-Tz)CR were synthesized using a method similar to

that used to synthesize 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)C (Figure 15). 99mTcO4- was
obtained from Memorial Sloan Kettering Cancer Center, freshly eluted with saline from a
99

Mo/99mTc generator. The 99mTcO4- was reduced from 99mTc(VII) to 99mTc(V), to fit in the N3S

chelate as the 99mTc=O adduct, using a saturated solution of Sn(II) tartrate, filtered with a 0.1μm
syringe filter, in the presence of L-FKCR. The reaction was allowed to proceed for 10 minutes
at 90°C before HPLC purification. The gamma peak believed to be the syn diastereomer due to
its position on the RP HPLC was collected and taken to dryness under high vacuum.169 The
product was reconstituted in anhydrous dimethyl sulfoxide (DMSO) and reacted with Tz-NHS
ester in the presence of N,N-Diisopropylethylamine (DIEA). The resulting 99mTc-FK(Tz)CR
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complex was purified using HPLC, taken to dryness, and reconstituted in phosphate buffered
saline (PBS) at a pH of 7.4.
The major peak of the 99mTc-FKCR HPLC profile was easily isolated and the shift in the
retention time following the reaction with the tetrazine-NHS ester (Tz-NHS) indicated a
successful coupling reaction (Figure 16).

Figure 15: Synthesis of 99mTc-FK(Tz)CR.

57

58

Figure 16: Radio HPLC showing 99mTc peptide and 99mTc-peptide-tetrazine. The change in
retention time using the same solvent gradient on the radio-HPLC from 99mTc-FKCR to 99mTcFK(Tz)CR indicates that the 99mTc-FKCR is reacting with the Tz-NHS ester.

The 99mTc-FK(PEG5-Tz)CR reaction scheme is identical to that of 99mTc-FK(Tz)CR,
except a tetrazine-PEG5-NHS ester (Tz-PEG5-NHS) is used in place of Tz-NHS. As before, the
change in retention time on the radio-HPLC from the 99mTc-FKCR to 99mTc-FK(Tz)CR indicated
that the 99mTc-FKCR is reacting with the Tz-PEG5-NHS ester.
Using the reaction scheme above (Figure 15) and the HPLC system described above, it
was not possible to sufficiently separate the more hydrophilic 99mTc-DKC from the 99mTcO4- and
various side products obtained in the HPLC void peak (
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Figure 17).
On the assumption that the 99mTc-DKC was formed but could not be separated using the
current HPLC system, the reaction with tetrazine was pursued without prior purification. The
new reaction scheme that eliminated the HPLC purification of 99mTc-DKC is shown in Figure
18. Notable features in this synthesis are: 1) filtration of the Sn tartrate prior to reaction with
99m

TcO4-; 2) no HPLC purification of 99mTc-DKC- simply drying down the entire reaction

mixture containing excess Sn tartrate; 3) reconstitution in DMSO and reaction with Tz-NHS
ester.
99m

TcO4- was obtained from Memorial Sloan Kettering Cancer Center. The 99mTcO4- was

reduced from 99mTc(VII) to 99mTc(V) using a saturated solution of Sn(II) tartrate, filtered with a
0.1μm syringe filter, in the presence of L-DKC. The reaction was allowed to proceed for 10
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minutes at 90°C, taken to dryness under high vacuum, reconstituted in anhydrous dimethyl
sulfoxide (DMSO), and reacted with Tz-NHS ester in the presence of N,NDiisopropylethylamine (DIEA). The resulting 99mTc-DK(Tz)C complex was purified using
HPLC, taken to dryness, and reconstituted in phosphate buffered saline (PBS) at a pH of 7.4.
The 99mTc-DK(Tz)C HPLC preparation (Figure 18) indicates that while a significant
percentage of the activity remains unreacted at the void, more than enough 99mTc-DK(Tz)C is
obtained that can be separated and used for preliminary studies; this is shown in the highlighted
area of the radiotrace in Figure 19.

Figure 17: Reaction scheme for the synthesis of 99mTc-DK(Tz)C. This approach eliminates the
first HPLC purification to isolate the 99mTc-DKC peptide and does not remove the excess tin.
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Figure 18: The radio-HPLC peak suspected to be 99mTc-DKC is too close to the HPLC void
peak (~3-5 minutes) and is therefore not easily isolated. This HPLC gradient is water and
acetonitrile (0.1% TFA) with the acetonitrile concentration increasing from 5-45% over
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Figure 19: Using the modified reaction scheme, the 99mTc-DK(Tz)C reaction mixture was
analyzed using a radio-HPLC. The region suspected to contain the 99mTc-DK(Tz)C (highlighted)
was collected for reinjection.

The 99mTc-DK(PEG5-Tz)C reaction scheme is identical to that of 99mTc-DK(Tz)C, except
that Tz-PEG5-NHS is used in place of Tz-NHS. The 99mTc-DK(PEG5-Tz)C had a similar
retention time to 99mTc-DK(Tz)C.
A very important finding in this set of experiments is that Sn can be likely utilized
directly in the reactions without compromising the integrity of the tetrazine. While further
optimization is required to improve radiochemical yields, this new reaction scheme indicates that
the Tz-NHS and Tz-PEG5-NHS is less sensitive to the presence of Sn than previously feared.
This finding is also encouraging for the synthesis of a N3S peptide-tetrazine ligand that can be
reacted with 99mTcO4- and Sn(II) in the last step.
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Due to the fact that 99mTc-SKC had an HPLC profile similar to that of 99mTc-DKC, the
new reaction scheme was used to synthesize 99mTc-SK(Tz)C. The 99mTc-SK(Tz)C and 99mTcSK(PEG5-Tz)C was successfully isolated from the reaction mixture.

2.7.2. Radio-TLC Results
For each complex, the first radio-TLC readout indicates that most of the 99mTc-peptide-Tz
complex moves with the solvent front while some activity remains at the origin (possibly in the
form of 99mTcO- or unreacted 99mTc-peptide complex). After reacting with BSA-TCO, most of
the activity moves to the origin, indicating a successful tetrazine-transcyclooctene “click”
reaction. This is supported by the fact that the solvent front peak disappears after purification
using a size-exclusion Sephadex G-25M PD-10 column (2.5 mL dead volume). Based on these
results all six modified 99mTc complexes contain viable tetrazine moieties that are reactive with
TCO (Figure 20, Figure 21, Figure 22, Figure 23, Figure 24, and Figure 25).
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Figure 20: Radio-TLC of 99mTc-FK(Tz)CR before and after reaction with BSA-TCO and before
and after purification with PD-10 size exclusion column.
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Figure 21: Radio-TLC of 99mTc-FK(PEG5-Tz)CR before and after reaction with BSA-TCO and
before and after purification with PD-10 size exclusion column.
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Figure 22: Radio-TLC of 99mTc-DK(Tz)C before and after reaction with BSA-TCO and before
and after purification with PD-10 size exclusion column.
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Figure 23: Radio-TLC of 99mTc-DK(PEG5-Tz)C before and after reaction with BSA-TCO and
before and after purification with PD-10 size exclusion column.
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Figure 24: Radio-TLC of 99mTc-SK(Tz)C before and after reaction with BSA-TCO and before
and after purification with PD-10 size exclusion column.
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Figure 25: Radio-TLC of 99mTc-SK(PEG5-Tz)C before and after reaction with BSA-TCO and
before and after purification with PD-10 size exclusion column.

2.7.3. Log P Results
The first complex tested, 99mTc-FK(Tz)C, was relatively lipophilic, with a Log P value of
1.0 ± 0.1. Increasing hydrophilicity tends to promote renal clearance and reduce intestinal
uptake, therefore modifications were made with the aim of lowering the Log P value.
For the 99mTc-peptide complexes, the cysteine is necessary to anchor the N3S 99mTc
complex and the lysine is required to react with the Tz-NHS ester. Consequently, to increase the
hydrophilicity of the complex, the phenylalanine (a nonpolar residue) was replaced with an
aspartic acid (a charged residue) and a serine (a polar residue). This worked, reducing the Log P
to -2.6 ± 0.2 for 99mTc-DK(PEG5-Tz)C and -0.9 ± 0.3 for 99mSK(PEG5-Tz)C. As an alternative to
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replacing the phenylalanine, an arginine (a charged residue) was added to the original complex,
forming 99mTc-FK(Tz)CR. This also reduced the Log P value to -0.5 ± 0.2
In addition to modifying the peptide backbone, the complexes were PEGylated by
reacting the 99mTc-peptide complexes with Tz-PEG5-NHS instead of Tz-NHS. PEGylation of the
Tz complexes successfully increased their hydrophilicities, as demonstrated by more negative
Log P values (Table 4), with the exception of 99mTc-DK(PEG5-Tz)C which had the same Log P
value as 99mTc-DK(Tz)C.

Complex

Log P

99m

Tc-FK(Tz)C

1.0± 0.1

99m

Tc-FK(PEG5-Tz)C

-0.3±0.02

99m

Tc-FK(Tz)CR
TC-FK(PEG5-Tz)CR

-0.5±0.2
-0.8±0.01

Tc-DK(Tz)C
Tc-DK(PEG5-Tz)C

-2.6±0.2
-2.6±0.1

99m

Tc-SK(Tz)C

-0.9±0.3

99m

Tc-SK(PEG5-Tz)C

-1.4±0.3

99m
99m
99m

Table 4: Mean logarithms of the partition coefficients of 99mTc complexes. Increased negative
values indicate increased levels of hydrophilicity.

3.8. Conclusion
All of the relevant 99mTc complexes were successfully synthesized and purified using an
HPLC system. The integrity of the Tz moieties were confirmed using Radio-TLC and the
increased hydrophilicity was demonstrated using the Log P values. It was determined that 99mTcFK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTc-SK(PEG5-Tz)C would be used in
subsequent in vivo studies to compare against 99mTc-FK(Tz)C.
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Although hydrophilicity is not a perfect predictor of whether a complex will clear from
the kidneys or intestines, more hydrophilic complexes tend to favor renal excretion and the
comparison of Log P values is a useful test before spending resources on in vivo experiments.
Similarly, “click” reactions will not necessarily occur in vivo even if the components are viable,
but it is important to establish their efficacy before working in an animal model.
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Chapter 4
Synthesis and characterization of Re-peptide
and Re-peptide-Tz constructs
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4.1. Introduction
Tc is an isotope that is available on the “tracer” level and that feature, along with its

99m

6.02 half-life, requires that a macroscopic analog be synthesized for complete characterization.
Due to the similarity of Tc and Re chemistry in the N3S (tripeptide) chelate, the macroscopic
complex using non-radioactive Re (often called the “cold” standard) were synthesized for each
of the 99mTc tri and tetra-peptide complexes chosen for in vivo study. These complexes were ReFKC, Re-FK(Tz)C, Re-FKCR, Re-FK(PEG5-Tz)CR, Re-DKC, Re-DK(PEG5-Tz)C, Re-SKC,
and Re-SK(PEG5-Tz)C and each was analyzed using LCMS. NMR analyses were then
performed on the most promising complex, Re-FK(PEG5-Tz)CR, and its precursor, Re-FKCR.
Coelutions of the Re and 99mTc complexes were then performed to verify that the macroscopic
structural data could be applied to the tracer complexes.

4.2. Synthesis
4.2.1. Synthesis of (Bu4N)[ReOBr4(H2O)] •2H2O
This rhenium starting material was prepared following the method of Rose et. al.178
Briefly, n-butylphosphine, PBun3 was dissolved in CH2Cl2 before Br2 in CH2Cl2 was added
dropwise. (Bu4N)ReO4 was then dissolved in CH2Cl2, added to the reaction mixture, and stirred
for 45 minutes at room temperature. Cyclohexene, diethyl ether, and pentane was added
sequentially to precipitate the purple product, which was collected via vacuum filtration. The
resulting (Bu4N)[ReOBr4(H2O)]•2H2O product showed the following IR (ATR, cm-1) stretches:
2959 (s), 2932 (m), 2873 (m), 1466 (s), 1380 (w), 1227 (w), 1103 (vs), 984 (vs), 903 (vs), 812
(w), 736 (m).
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4.2.2. Synthesis of Re-FKC
10.0 mg (16.8 μmol) of peptide (FKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (18.3
mg, 22.3 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 16.2-17.1 minutes and lyophilized overnight to dryness.

4.2.3. Synthesis of Re-FK(Tz)C
Lyophilized Re-FKC was reconstituted in 300 μL DMSO. Tz-NHS (25 mg/mL in
DMSO) was added to the solution (in a Re-FKC:Tz-NHS molar ratio of 1:1.1). 5 μL N,Ndiisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 27.3-28.6
minutes and lyophilized overnight to dryness.

4.2.4. Synthesis of Re-FKCR
10 mg (13.3 μmol) of peptide (FKCR) was reacted with TBA[ReOBr4(H2O)]•2H2O (13.7
mg, 16.7 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to
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the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 26.0-26.8 minutes and lyophilized overnight to dryness.

4.2.5. Synthesis of Re-FK(PEG5-Tz)CR
Lyophilized Re-FKCR was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in
DMSO) was added to the solution (in a Re-FKCR:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL
N,N-diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 26.0-27.5
minutes and lyophilized overnight to dryness.

4.2.6. Synthesis of Re-DKC
10 mg (17.8 μmol) of peptide (DKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (20.7
mg, 25.3 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 3.0-5.2 minutes and lyophilized overnight to dryness.
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4.2.7. Synthesis of Re-DK(PEG5-Tz)C
Lyophilized Re-DKC was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in
DMSO) was added to the solution (in a Re-DKC:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL N,Ndiisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 20.0-22.3
minutes and lyophilized overnight to dryness.

4.2.8. Synthesis of Re-SKC
10 mg (18.7 μmol) of peptide (SKC) was reacted with TBA[ReOBr4(H2O)]•2H2O (22.5
mg, 27.4 μmol) in the presence of sodium acetate (in a molar ratio of 1:0.9:1.8) in 300 μL of
MeOH. The reaction was allowed to proceed for 60 minutes at 40°C. 700 μL H2O was added to
the reaction mixture and the solution was stirred. The 1 mL solution was HPLC purified using a
Waters Symmetry C18 3.5 μm 100 Å analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic
acid in water (solvent A) and acetonitrile (solvent B) mobile phase. The product was collected at
a retention time of 3.0-5.2 minutes and lyophilized overnight to dryness.

4.2.9. Synthesis of Re-SK(PEG5-Tz)C
Lyophilized Re-SKC was reconstituted in 300 μL DMSO. Tz-PEG5-NHS (25 mg/mL in
DMSO) was added to the solution (in a Re-SKC:Tz-PEG5-NHS molar ratio of 1:1.1). 5 μL N,N77

diisopropylethylamine (DIEA) was added and the reaction was allowed to proceed for 30
minutes at room temperature. 500 μL H2O was added to the reaction mixture and the solution
was stirred. The product was HPLC purified using a Waters Symmetry C18 3.5 μm 100 Å
analytical column 4.6 x 150 mm and a 0.1% trifluoroacetic acid in water (solvent A) and
acetonitrile (solvent B) mobile phase. The product was collected at a retention time of 21.3-23.5
minutes and lyophilized overnight to dryness.

4.3. HPLC Analyses
All analytical and preparatory HPLC methods used during the syntheses of these
compounds were performed using a VARIAN ProStar UV-vis HPLC system interfaced with a
NaI detector and a Tennelec Minibin power supply, high voltage supply, and amplifier. All
HPLC experiments monitored the 99mTc γ emissions as well as the absorbance units at λ =
260nm. The mobile phase consisted of 0.1% trifluoroacetic acid in (A) H2O and (B) acetonitrile.
A Waters Symmetry C18 5μm 4.6x100mm column was used with various mobile phase gradients
(e.g. 5-45% B over 40 minutes).

4.4. LCMS Analyses
Mass spectral data was obtained on a LCMS system comprised of an Agilent 1200 LC
system coupled to an Agilent 6340 ion trap mass spectrometer. Samples were injected onto an
Agilent Zorbax column (SB-C8, 5 uM, 2.1 x 50 mm) using a linear gradient of 5-95%
acetonitrile in water (0.5% formic acid) over 10 minutes. The samples were prepared by

78

dissolving the lyophilized Re-peptide and Re-peptide-Tz samples in water:acetonitrile solution
(v:v, 950:50 μL).

4.5. NMR Analyses
The 1D proton and 2D TOCSY (total correlation spectroscopy) NMR spectra were
obtained from a Bruker Avance III 600 MHz with a TCI cryoprobe NMR spectrometer with
chemical shift referenced to H2O, at T=296 K. Re-FKCR, the precursor to the lead complex ReFK(PEG5-Tz)CR, and free ligand FKCR samples (5-10 mg) were dissolved in 700 μL D2O. 1D
proton NMR spectra were collected at 8 scans. 2D TOCSY scans were collected at 2 scans, 256
increments.

4.6. Coelution of 99mTc and Re constructs
Purified 99mTc-FKCR, 99mTc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTcSK(PEG5-Tz) were coeluted with their cold, macroscopic rhenium analogs. Resulting from the
sequence of the UV and radio detectors in this HPLC system, UV active species are expected to
elute 1 minute before radio detection.
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4.7. Results and Discussion
4.7.1. LCMS Results
The m/z values for the molecular ion [M + H]+ peaks obtained through LCMS analyses,
along with the molecular weights (MW) calculated from the proposed structures, are included in
Table 5.

Complex
Re-FKC
Re-FK(Tz)C
Re-FKCR
Re-FK(PEG5-Tz)CR
Re-DKC
Re-DK(PEG5-Tz)C
Re-SKC
Re-SK(PEG5-Tz)C

Theoretical MW (g/mol)

Experimental MW (g/mol)

+

[M + H] m/z
596.1
879.2
752.2
1241.5
564.1
1053.3
536.1
1025.3

[M + H]+ m/z
596.2
879.5
752.5
1242.1
564.3
1053.6
536.0
1025.4

Table 5: Theoretical molecular weights for proposed Re-peptide and Re-peptide-Tz structures
with experimental molecular weight values obtained through LCMS.

4.7.2. NMR Results
The chemical shift (ppm) values from the 1H NMR spectra of the macroscopic Re-FKCR
and Re-FK(PEG5-Tz)CR were compared to the free FKCR ligand (Table 6). In order to assist in
the deconvolution of the 1H NMR chemical shifts and make appropriate assignments, 2D
TOCSY spectra was obtained (Figure 27 and Figure 29). Although the signals observed were
not strong enough to assign every hydrogen, particularly for Re-FK(PEG5-Tz)CR wherein low
yields hampered characterization efforts, the 2D deconvolution was sufficient to identify
hydrogens in each amino acid of the chelated FKCR complex.
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F

K

C

R

HN
Hα (1H)
Hβ (2H)
2,6H-Aryl (2H)
3,5H-Aryl (2H)
4H-Aryl (1H)
HN
Hα (1H)
Hβ (2H)
Hγ (2H)
Hδ (2H)
Hε (2H)
HN
Hα (1H)

FKCR
8.12
4.32
3.08
7.27
7.13
7.27
7.81
1.75
1.26
1.63
2.84
8.35
-

Hβ (2H)

4.14

HN
Hα (1H)

8.11
4.23
1.65
1.63
1.63
3.08

Hβ (2H)
Hγ (2H)
Hδ (2H)

Re-FKCR
4.34
3.43
7.25
7.25
7.25
4.74
1.9
1.15
1.56
2.8
4.92
3.85
3.4
4.11
1.72
1.62
1.61
3.08

Re-FK(PEG5-Tz)CR
4.38
3.38
7.45
7.32
7.45
4.79
2.95
4.90
3.41
3.19
4.12
1.60
1.60
-

Table 6: 1H NMR chemical shifts (ppm) for Re-FKCR and Re-FK(PEG5-Tz)CR compared to
the free ligand FKCR.
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Figure 26: 1H NMR assignment of Re-FKCR.

Figure 27: TOCSY 2D NMR assignment of Re-FKCR.
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Figure 28: 1H NMR assignment of Re-FK(PEG5-Tz)CR.

Figure 29: TOCSY 2D NMR assignment of Re-FK(PEG5-Tz)CR.
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4.7.3. Coelution Results
As expected from the arrangement of the HPLC system, the Re-peptide and Re-peptideTz UV traces eluted approximately one minute earlier than the corresponding 99mTc-peptide and
99m

Tc-peptide-Tz radio-traces (Figure 30, Figure 31, Figure 32, and Figure 33). This indicates

that the data obtained for the Re complexes can be used a surrogate for the tracer level 99mTc
complexes.

Figure 30: Coelution of 99mTc-FKCR (radio-trace) and Re-FKCR (260 nm UV trace).
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Figure 31: Coelution of 99mTc-FK(PEG5-Tz)CR (radio-trace) and Re-FK(PEG5-Tz)CR (260 nm
UV trace).

Figure 32: Coelution of 99mTc-DK(PEG5-Tz)C (radio-trace) and Re-DK(PEG5-Tz)C (260 nm
UV trace).
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Figure 33: Coelution of 99mTc-SK(PEG5-Tz)C (radio-trace) and Re-SK(PEG5-Tz)C (260 nm UV
trace).

4.8. Conclusion
The Re-peptide and Re-peptide-Tz complexes synthesized, Re-FKC, Re-FK(Tz)C, ReFKCR, Re-FK(PEG5-Tz)CR, Re-DKC, Re-DK(PEG5-Tz)C, Re-SKC, and Re-SK(PEG5-Tz)C,
matched the expected HPLC retention times and their theoretical MWs were closely
approximated by the experimental MWs observed through LCMS. Coelution studies confirmed
that structural data obtained for the Re analogs could be extended to the 99mTc complexes used
for subsequent in vivo studies.
As noted earlier discussions, two major product peaks were observed for each Re-peptide
and Re-peptide-Tz HPLC purification. Based on the thorough characterization performed on ReFKC in previous work in this laboratory, as well as LCMS analyses, it is believed that these
peaks correspond to the anti and syn diastereomers, defined by the relative positions of the
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oxygen on the Re and the lysine in the peptide chelator.169 In all cases, the second peak, likely
the syn diastereomer, was collected and purified. This diastereomer was produced in a higher
yield than the anti diastereomer, which contributed to the choice to focus on its characterization
and the corresponding 99mTc complex for use in vivo. The exact nature of the presumed
diastereometric relationship is worth exploring in future work, but was less pressing than
providing a pure product for in vivo testing and potential clinical translation.
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Chapter 5
In Vivo Studies

88

5.1. Introduction
As previously discussed, a pretargeted 99mTc SPECT imaging agent will be considered
viable if it is isolatable, can react in vivo with modified antibodies, and produces a high tumor-tobackground ratio. All of the complexes tested in vivo, 99mTc-FK(Tz)C, 99mTc-FK(PEG5-Tz)CR,
99m

Tc-DK(PEG5-Tz)C, and 99mTc-SK(PEG5-Tz)C, were isolated and confirmed to have Tz

moieties that react with TCO. They were chosen over the other complexes, 99mTc-FK(Tz)CR,
99m

Tc-DK(Tz)C, and 99mTc-SK(Tz)C, due to their greater hydrophilicities, as demonstrated by

more negative Log P values, as well as the published benefits of using PEGylated Tz
complexes.123
Biodistribution and blood half-life studies were performed in healthy athymic mice to
determine which complex exhibited the optimal excretory characteristics and should be allocated
the greatest resources for subsequent studies in SW1222 tumor-bearing mice. Biodistributions
and pretargeted SPECT/CT imaging was then performed in these tumor-bearing mice.

5.2. Blood Half-life Methods
Blood half-life studies were completed for 99mTc-FK(PEG5-Tz)CR and 99mTc-SK(PEG5Tz)C by injecting 50 to 60 µCi of each radiolabeled complex into healthy athymic nude female
mice 6-8 weeks old intravenously via the tail vein. Mice were sacrificed 5 minutes, 15 minutes,
30 minutes, 1 hour, 2 hours, and 4 hours post injection (n = 4 for each time point). Terminal
blood draws were collected via cardiac puncture and the blood was weighed before the activity
was counted. Counting was performed on a Perkin Elmer Automatic Wizard γ-counter and the
percent injected dose per gram (%ID/g) was calculated and reported. The biphasic exponential
decay was then calculated using a nonlinear regression via Prism.
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5.3. Biodistribution Studies in Healthy Mice
The biological distribution of the 99mTc-FK(Tz)C complex was determined in healthy
athymic nude female mice 6-8 weeks old. Approximately 50-60 µCi of the radiolabeled complex
was injected intravenously into the mice via the tail vein. Mice were sacrificed 30 minutes, 1
hour, 2 hours, and 4 hour post injection (n = 5 per time point). The following tissues were
collected; blood, tail, heart, lungs, liver, spleen, stomach, small intestines, large intestines,
kidneys, muscle, bone, and skin. The tissues were then counted on a Perkin Elmer Automatic
Wizard γ-counter and the percent injected dose per gram (%ID/g) was calculated and reported.
This method was then repeated using the three most promising alternative complexes,
99m

Tc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTc-SK(PEG5-Tz)C.

5.2. A33 Modification with TCO
The A33 antibody was modified with transcyclooctene-NHS as described by Zeglis et.
al.112 5 mg A33 was dissolved in 500 µL PBS. The pH was adjusted to 8.8 – 8.9 using 0.1M
NaHCO3. Sufficient TCO-NHS in N,N-dimethylformamide (25mg/mL) was then added and the
solution was mixed at 350 rpm for 1 hour at 25°C. The antibody was purified using a sizeexclusion Sephadex G-25M PD-10 column (2.5 mL dead volume) and concentrated using
centrifugal filtration units with a 50,000 molecular weight cut off.
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5.4. Biodistribution Studies in Tumor-Bearing Mice
Pretargeting experiments were performed using all four complexes, 99mTc-FK(Tz)C,
99m

Tc-FK(PEG5-Tz)CR, 99mTc-SK(PEG5-Tz)C, and 99mTc-DK(PEG5-Tz)C. For each complex,

athymic nude female mice 6-8 weeks old bearing subcutaneous SW1222 xenografts (right
shoulder, 100 -150 mm3, 14-21 days post-inoculation) were administered 125 µg. A33-TCO (in
250 µL PBS) via tail vein injection. After 24 hours, 50-60 µCi of each complex was injected.
After an appropriate post-injection delay (1 hour, 4 hours, and/or 8 hours), the animals were
sacrificed using CO2 asphyxiation. The following tissues were collected; blood, tail, heart, lungs,
liver, spleen, stomach, small intestines, large intestines, kidneys, muscle, bone, skin, and tumor.
The tissues were then counted on a Perkin Elmer Automatic Wizard γ-counter and the percent
injected dose per gram (%ID/g) were calculated and reported.
The above procedure was repeated without A33-TCO (using a blank 250 µL PBS initial
injection) for 99mTc-FK(PEG5-Tz)CR to control for passive uptake.
For 99mTc-FK(Tz)C, the baseline complex, mice were sacrificed 1 hour, 4 hours, and 8
hours post injection (n = 3 per time point). For pretargeting with 99mTc-FK(PEG5-Tz)CR, the
lead complex, mice were sacrificed 1 hour, 4 hours, and 8 hours post injection (n = 5 per time
point). For the control with 99mTc-FK(PEG5-Tz)CR mice were sacrificed 4 hours post injection
(n = 4). For 99mTc-DK(PEG5-Tz)C and 99mTc-SK(PEG5-Tz)C, mice were sacrificed 4 hours post
injection (n = 2 per complex).
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5.5. SPECT/CT Imaging Studies
Pretargeting SPECT imaging experiments were conducted on a NanoSPECT/CT Plus In
Vivo Animal Imager. Athymic nude female mice 6-8 weeks old bearing subcutaneous SW1222
xenografts (right shoulder, 100 -150 mm3, 14-21 days post-inoculation) were administered 125
µg. A33-TCO (in 250 µL PBS) via tail vein injection. After 24 hours, 400 µCi of each complex
(99mTc-FK(Tz), 99mTc-FK(PEG5-Tz)CR, 99mTc-DK(PEG5-Tz)C, and 99mTc-SK(PEG5-Tz)C) was
injected into separate mice pretargeted with the A33-TCO. Prior to imaging mice were
anesthetized by inhalation of a 2% isofluorane: oxygen gas mixture and placed on a scanner bed.
SPECT data was obtained for each mouse at 1 hour, 4 hour and 8 hours post injection.
The above procedure was repeated without A33-TCO (using a blank 250 µL PBS initial
injection) to control for passive uptake. Was this for all or only for Tc99m FK(PEG5Tz)CR?
Please be specific here.
“Pre-clicked” SPECT imaging experiments were conducted using the same instrument
and cohort of SW1222 tumor-bearing mice used for the above pretargeting experiments. The
mice were injected with 400 µCi of “pre-clicked” 99mTc-FK(Tz-TCO-A33)C or 99mTc-FK(PEG5Tz-TCO-A33)CR, anesthetized by inhalation of a 2% isofluorane: oxygen gas mixture, and
placed on a scanner bed. SPECT data was obtained for each mouse at 1 hour, 4 hour and 8 hours
post injection.

5.6. Results and Discussion
5.6.1. Blood Half-life Results
For the in vivo “click” reaction to occur, the tetrazine-containing radioligand complex
needs to circulate in the blood pool for a sufficient period of time. If the clearance is too fast,
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there will not be enough time for an appreciable accumulation at the target site. Consequently,
blood half-life studies are important and were performed. These studies will help determine
which of the complexes should be selected for imaging studies.
The nonlinear regressions were very strongly fit to the data (R2 = 1.00 for 99mTc-FK(Tz)C
(Figure 34), 99mTc-FK(PEG5-Tz)CR (Figure 35), and 99mTc-DK(PEG5-Tz)C (Figure 36); R2 =
0.99 for 99mTc-SK(PEG5-Tz)C (Figure 37)) and both fast and slow blood half-life clearance
values were obtained (Table 7). It’s important to note that fast clearance represents the drug
complexes initial circulation and excretion whereas the slow represents the gradual, subsequent
release from tissues that absorbed the product.
The fast blood half-life value of 7.4 minutes is likely sufficient for the in vivo tetrazinetranscylooctene reaction and, coupled with the biodistribution data, suggests that 99mTcFK(PEG5-Tz)CR is the lead compound that will be tested in subsequent imaging studies.

99m

Tc-FK(Tz)C

Half-Life (Fast)
Half-Life (Slow)
Percent Fast
R2

99m

16.64 mins
6.38 hrs
62.8%

Tc-FK(PEG5-Tz)CR
7.37 mins
1.90 hrs
78.9%

1.00

1.00

99m

Tc-DK(PEG5-Tz)C
8.64 mins
4.91 hrs
72.0%

99m

1.00

Table 7: Biphasic elimination of 99mTc-peptide-Tz complexes.
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Tc-SK(PEG5-Tz)C
4.98 mins
3.31 hrs
77.2%
0.99

99m

Tc-FK(Tz)C %ID/g in Blood ( n = 4; R2 = 1.00).

Figure 34: Non-linear regression of

Figure 35: Non-linear regression of

99m

Tc-FK(PEG5-Tz)CR %ID/g in Blood ( n = 4; R2 = 1.00).
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Figure 36: Non-linear regression of
1.00).

Figure 37: Non-linear regression of

99m

Tc-DK(PEG5-Tz)C %ID/g in Blood ( n = 4; R2 =

99m

Tc-SK(PEG5-Tz)C %ID/g in Blood ( n = 4; R2 = 0.99).
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5.6.2. Biodistribution Studies in Healthy Mice Results
Although all four complexes exhibited high intestinal uptake, 99mTc-FK(PEG5-Tz)CR
exhibited lower large intestine uptake (20.8±10.4 %ID/g) after 4 hours than did 99mTc-FK(Tz)C
(65.7±22.1 %ID/g), 99mTc-SK(PEG5-Tz)C (36.8±3.5 %ID/g), and 99mTc-DK(PEG5-Tz)C
(50.8±9.9 %ID/g) (Table 8, Table 9, Table 10, and Table 11). The improved clearance can be
clearly visualized by observing the comparisons between the uptake in the key excretory organs
(the blood, liver, small intestine, large intestine, and kidneys) 30 minutes (Figure 38), 1 hour
(Figure 39), 2 hours (Figure 40), and 4 hours post-injection (Figure 41). These results indicated
that 99mTc-FK(PEG5-Tz)CR was the most likely candidate for providing a SPECT image with
reduced background/non-target to target activity and a clearer tumor image.

99m

Tc-FK(Tz)C %ID/g ± S.D.

Organ

30 mins

1 hour

2 hours

4 hours

Blood

5.4±3.5
1.0±0.3
0.9±0.5
2.0±0.4
20.2±8.1
1.0±0.1
2.5±0.6
48.7±9.9
0.2±0.0
2.9±0.5
0.5±0.1
0.8±0.2
0.9±0.3

1.8±0.3
0.8±0.0
0.5±0.1
1.6±0.5
18.0±4.9
0.8±0.2
1.7±0.7
57.7±27.5
0.4±0.3
2.4±0.2
0.6±0.1
0.5±0.1
0.7±0.1

2.0±0.7
0.8±0.1
0.5±0.1
1.6±0.8
13.2±4.5
1.0±0.3
3.3±2.0
12.8±8.0
45.8±13.2
2.7±0.3
0.9±0.5
0.6±0.2
0.9±0.3

1.3±0.2
0.7±0.1
0.4±0.0
1.3±0.1
5.7±1.1
0.9±0.2
1.5±0.8
3.6±1.5
65.7±22.1
3.2±0.3
0.9±0.5
0.5±0.0
0.8±0.4

Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin

Table 8: Biodistribution of 99mTc-FK(Tz)C in healthy mice (n = 5 mice per time point).
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99m

Tc-FK(PEG5-Tz)CR %ID/g ± S.D.

Organ

30 mins

1 hour

2 hours

4 hours

Blood

5.6±0.9
2.1±0.2
1.4±0.3
2.9±0.8
10.3±1.9
1.2±1.1
2.5±0.7
30.1±11.5
0.2±0.1
4.2±0.6
0.2±0.1
0.2±0.2
1.0±0.5

2.7±1.5
1.7±0.3
0.8±0.1
2.2±0.4
13.4±3.8
1.2±1.6
3.1±1.1
42.2±8.9
0.2±0.1
3.6±0.5
0.2±0.1
0.4±0.1
0.8±0.1

1.7±0.3
1.8±1.8
0.5±0.1
1.3±0.3
3.4±2.6
0.7±0.9
2.7±0.5
11.6±7.3
25.8±10.3
2.7±0.4
0.1±0.1
0.1±0.1
0.4±0.1

0.9±0.2
0.8±0.2
0.2±0.1
0.8±0.2
2.1±1.1
0.4±0.3
1.7±0.9
3.2±1.7
20.8±10.4
2.3±0.3
0.1±0.1
0.2±0.2
0.3±0.1

Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin

Table 9: Biodistribution of 99mTc-FK(PEG5-Tz)CR in healthy mice (n = 5 mice per time point).
99m

Tc-DK(PEG5-Tz)C %ID/g ± S.D.

Organ

30 mins

1 hour

2 hours

4 hours

Blood

2.8±1.0
0.9±0.1
0.6±0.0
1.5±0.8
11.1±9.3
2.3±1.3
2.8±2.9
57.4±23.4
1.4±2.2
3.9±0.6
0.5±0.2
0.7±0.2
0.9±0.4

1.6±0.3
0.9±0.5
0.6±0.1
1.9±0.2
4.9±2.2
1.9±1.4
2.6±1.1
61.6±17.4
4.5±8.3
3.8±0.5
0.5±0.2
0.6±0.1
0.6±0.1

4.2±2.3
0.6±0.2
0.6±0.1
1.7±0.3
5.3±4.1
0.8±0.4
2.0±0.7
28.5±17.5
38.2±3.6
3.1±0.4
0.6±0.2
0.5±0.1
0.6±0.1

1.2±0.2
0.4±0.1
0.4±0.1
1.3±0.6
1.2±0.9
0.7±0.5
1.4±0.2
3.2±4.9
50.8±9.9
2.8±0.6
0.5±0.3
0.5±0.1
0.6±0.2

Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin

Table 10: Biodistribution of 99mTc-DK(PEG5-Tz)C in healthy mice (n = 5 mice per time point).
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99m

Tc-SK(PEG5-Tz)C %ID/g ± S.D.

Organ

30 mins

1 hour

2 hours

4 hours

Blood

1.6±0.2
0.9±0.3
0.5±0.1
1.9±0.3
8.9±6.6
0.4±0.2
5.6±4.4
44.3±8.5
0.2±0.1
4.3±1.0
0.4±0.1
0.5±0.1
0.6±0.1

1.2±0.5
0.6±0.2
0.7±0.2
2.5±1.3
2.8±1.6
0.6±0.0
3.3±1.6
37.7±21.5
1.6±0.9
4.6±0.8
0.4±0.1
0.4±0.1
0.7±0.2

0.9±0.2
0.5±0.1
0.5±0.1
1.3±0.2
2.1±0.9
0.4±0.1
4.7±0.8
15.8±17.4
34.5±17.1
3.5±0.1
0.5±0.1
0.4±0.1
0.6±0.0

0.8±0.2
0.5±0.2
0.3±0.0
1.0±0.3
3.6±2.2
0.3±0.1
1.4±0.3
2.8±0.4
36.8±3.5
3.1±0.4
0.6±0.3
0.4±0.0
0.5±0.1

Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin

Table 11: Biodistribution of 99mTc-SK(PEG5-Tz)C in healthy mice (n = 5 mice per time point).
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Figure 38: Biodistribution in healthy mice comparison 30 minutes post-injection.
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Figure 39: Biodistribution comparison in healthy mice 1 hour post-injection.
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Figure 40: Biodistribution comparison in healthy mice 2 hours post-injection.
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Figure 41: Biodistribution comparison in healthy mice 4 hours post-injection.

5.6.3. Biodistribution Studies in Tumor-Bearing Mice Results

As observed in the biodistributions in healthy mice, all four pretargeted complexes had
high intestinal uptake four hours post-injection, but 99mTc-FK(PEG5-Tz)CR had the lowest
(29.0±8.5 %ID/g) (Table 12, Table 13, Table 15, and Table 16). 99mTc-FK(PEG5-Tz)CR also
had the highest tumor uptake four hours post injection with 1.8±0.3 %ID/g compared to 1.0±0.2
%ID/g for 99mTc-FK(Tz)C, 0.5±0.0 %ID/g for 99mTc-DK(PEG5-Tz)C, and 0.6±0.2 %ID/g for
99m

Tc-SK(PEG5-Tz)C. Notably, the tumor uptake for the untargeted (i.e. lacking any A33) 99mTc-

FK(PEG5-Tz)CR of 0.6±0.3 %ID/g was comparable to that of the pretargeted 99mTc-DK(PEG5102

Tz)C and 99mTc-SK(PEG5-Tz)C, indicating that neither of complexes demonstrated appreciable
in vivo “click” reactions and non-passive uptake and/or retention on the tumor (Table 14 and
Figure 45). While 99mTc-FK(Tz)C and 99mTc-FK(PEG5-Tz)CR moved from the small intestine to
the large intestine, the %ID/g was maintained on the tumor site, indicating the persistence of the
targeting (Figure 42, Figure 43, and Figure 44).
Pretargeted 99mTc-FK(Tz)C had a baseline tumor:large intestine %ID/g of 1:39.9 four
hours post-injection. One major goal of this project was to improve this ratio by both increasing
tumor uptake and decreasing intestinal uptake. Both 99mTc-DK(PEG5-Tz)C and 99mTc-SK(PEG5Tz)C failed with ratios of 1:66.2 and 1:65.8 respectively. 99mTc-FK(PEG5-Tz)CR was successful,
however, with a ratio of 1:15.7. Despite the relatively high large intestinal uptake remaining, this
result justified 99mTc-FK(PEG5-Tz)CR’s status as the lead complex of those tested. The full
tumor:background comparison can be seen in Table 17.

99m

Organ
Blood
Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin
Tumor

Tc-FK(Tz)C %ID/g ± S.D.
1 hour
4 hours
2.0±0.3
2.5±1.0
0.4±0.0
0.8±0.5
0.6±0.1
0.8±0.1
1.4±0.0
1.3±0.1
15.6±7.3
4.1±2.0
2.3±2.1
2.4±2.4
5.2±1.2
4.1±1.4
4.9±1.5
3.3±1.3
52.1±0.9
39.6±6.6
1.8±0.3
2.0±0.3
1.5±0.5
2.1±0.6
0.8±0.2
1.2±0.0
1.7±0.5
1.8±0.3
1.0±0.1
1.0±0.2

8 hours
2.5±1.2
1.1±0.9
0.9±0.1
1.6±0.4
3.1±1.1
2.9±2.8
3.8±1.3
5.8±3.0
46.1±5.9
2.3±0.6
3.4±1.1
1.6±0.1
1.9±0.5
1.2±0.6

Table 12: 99mTc-FK(Tz)C A33-TCO pretargeting biodistribution with SW1222 tumor-bearing
mice (n = 3)
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99m

Organ
Blood
Tail
Heart
Lungs
Liver
Spleen
Stomach
Sm. Intestine
Lg. Intestine
Kidneys
Muscle
Bone
Skin
Tumor

Tc-FK(PEG5-Tz)CR %ID/g ± S.D.
1 hour
4 hours
8 hours
5.4±0.4
4.6±3.6
1.6±0.3
0.6±0.0
0.5±0.3
0.3±0.1
1.3±0.1
0.8±0.1
0.5±0.1
3.5±0.4
2.3±0.4
1.0±0.2
8.4±6.8
3.9±3.1
2.1±1.6
2.7±3.1
1.4±1.6
1.0±1.3
9.1±2.6
9.6±2.7
9.0±8.8
45.7±13.5
2.7±1.4
3.6±4.7
4.7±5.1
29.0±8.5
17.5±3.1
4.9±0.3
3.4±0.3
2.2±0.3
0.6±0.2
0.5±0.3
0.3±0.1
1.1±0.2
0.6±0.1
0.4±0.1
1.5±0.2
1.0±0.2
0.8±0.1
1.8±0.1
1.8±0.3
1.7±0.3

Table 13: 99mTc-FK(PEG5-Tz)CR A33-TCO pretargeting biodistribution with SW1222 tumorbearing mice (n = 5)
99m

Tc-FK(PEG5-Tz)CR %ID/g ± S.D.
Organ
4 hours
Blood
3.2±2.4
Tail
0.6±0.2
Heart
0.4±0.1
Lungs
1.5±0.6
Liver
4.2±3.2
Spleen
1.8±2.0
Stomach
14.0±1.9
Sm. Intestine
3.5±1.3
Lg. Intestine
24.8±8.9
Kidneys
3.7±0.4
Muscle
0.3±0.0
Bone
0.4±0.1
Skin
0.6±0.4
Tumor
0.6±0.3

Table 14: 99mTc-FK(PEG5-Tz)CR untargeted control biodistribution with SW1222 tumorbearing mice (n = 4)
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99m

Tc-DK(PEG5-Tz)C %ID/g ± S.D.
Organ
4 hours
Blood
3.4±0.1
Tail
0.2±0.0
Heart
0.4±0.0
Lungs
0.9±0.0
Liver
1.7±0.6
Spleen
0.4±0.0
Stomach
1.1±0.1
Sm. Intestine
3.2±0.2
Lg. Intestine
31.2±2.5
Kidneys
2.4±0.0
Muscle
0.5±0.2
Bone
0.3±0.0
Skin
0.6±0.1
Tumor
0.5±0.0

Table 15: 99mTc-DK(PEG5-Tz)C A33-TCO pretargeting biodistribution with SW1222 tumorbearing mice (n = 2)

99m

Tc-SK(PEG5-Tz)C %ID/g ± S.D.
Organ
4 hours
Blood
1.1±0.2
Tail
0.6±0.4
Heart
0.4±0.0
Lungs
0.8±0.2
Liver
0.7±0.2
Spleen
0.3±0.0
Stomach
1.5±0.0
Sm. Intestine
2.6±2.5
Lg. Intestine
37.1±12.3
Kidneys
3.3±0.6
Muscle
0.4±0.1
Bone
0.3±0.1
Skin
0.4±0.1
Tumor
0.6±0.2

Table 16: 99mTc-SK(PEG5-Tz)C A33-TCO pretargeting biodistribution with SW1222 tumorbearing mice (n = 2)
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Figure 42: A33-TCO pretargeting comparison 1 hour post-injection.
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Figure 43: A33-TCO pretargeting comparison 4 hours post-injection.
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Figure 44: A33-TCO pretargeting comparison 8 hours post-injection.
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Figure 45: A33-TCO pretargeting control (99mTc-FK(PEG5-Tz)CR injected without A33-TCO)
comparison 4 hours post-injection.
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Time (post-injection)
1 hour

Tumor:Organ %ID/g
Tc-FK(Tz)C pretargeting

99m

Organ
Blood

1 : 2.0
1 : 15.1
1 : 2.3
1 : 4.8
1 : 50.7
1 : 1.7
1 : 2.5
1 : 4.2
1 : 3.4
1 : 39.9
1 : 2.0
1 : 2.0
1 : 2.5
1 : 4.7
1 : 37.0
1 : 1.8

Liver
Spleen
Sm. Intestine
Lg. Intestine
Kidneys

4 hour

Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

8 hour

Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

Time
1 hour

99m

Organ

Tc-FK(PEG 5-Tz)CR pretargeting
1 : 2.9
1 : 4.6
1 : 1.4
1 : 24.8
1 : 2.6
1 : 2.7
1 : 2.5
1 : 2.1
1 : 1.4
1 : 15.7
1 : 1.9
1 : 1.0
1 : 1.2
1 : 2.1
1 : 10.4
1 : 1.3

Blood
Liver
Spleen
Sm. Intestine
Lg. Intestine
Kidneys

4 hour

Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

8 hour

Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

Time
4 hour

99m

Organ
Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

Time
4 hour

99m

Organ
Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

Time
4 hour

Tc-DK(PEG 5-Tz)C pretargeting
1 : 7.2
1 : 3.6
1 : 6.9
1 : 66.2
1 : 5.1
Tc-SK(PEG 5-Tz)C pretargeting
1 : 2.0
1 : 1.3
1 : 4.6
1 : 65.8
1 : 5.8

99m

Organ
Blood
Liver
Sm. Intestine
Lg. Intestine
Kidneys

Tc-FK(PEG 5-Tz)CR control
1 : 5.4
1 : 7.2
1 : 6.1
1 : 42.5
1 : 6.3

Table 17: Tumor:Organ %ID/g comparison for pretargeted 99mTc-peptide-Tz complexes.
Decreased ratios compared to 99mTc-FK(Tz)C shown as green. Increased ratios compared to
99m
Tc-FK(Tz)C shown as red.
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5.6.4. SPECT/CT Imaging

As expected, when 99mTc-FK(Tz)C was “pre-clicked” with A33-TCO and injected into an
SW 1222 tumor-bearing mouse the tumor was clearly imaged with SPECT/CT six hours postinjection (Figure 46). This control confirmed the targeting of the radiolabeled MAb complex and
established a baseline for comparison against pretargeted images. When another tumor-bearing
mouse was pretargeted with A33-TCO and injected with 99mTc-FK(Tz)C 24 hours later (Figure
47), the tumor was clearly delineated, indicating a successful in vivo Tz-TCO “click,” but high
uptake in the intestines compromised the quality of the image. The control, wherein a tumorbearing mouse was injected with PBS followed 24 hours later by 99mTc-FK(Tz)C and SPECT/CT
imaging four hours post-injection (Figure 48), confirmed that the accumulation in the
pretargeted tumor was not due solely to passive effects.
The images obtained for 99mTc-FK(PEG5-Tz-TCO-A33)CR (Figure 49), 99mTcFK(PEG5-Tz)CR with pretargeted A33-TCO (Figure 50) and untargeted 99mTc-FK(PEG5-Tz)CR
(Figure 51) were comparable to those obtained using 99mTc-FK(Tz)C despite the improved
tumor:background ratios previously discussed. This indicates that while 99mTc-FK(PEG5-Tz)CR
represented an incremental improvement over the original complex tested, 99mTc-FK(Tz)C, its
intestinal uptake remains too high for translation to the clinic. In both cases, the in vivo “click”
reaction was confirmed with SPECT/CT, but complexes with more favorable pharmacokinetic
and clearance characteristics will need to be investigated.
The tumors could not be effectively delineated in either of the SPECT/CT images
obtained from 99mTc-DK(PEG5-Tz)C or 99mTc-SK(PEG5-Tz)C pretargeted with A33-TCO
(Figure 52 and Figure 53). These images were essentially identical to the untargeted controls
(Figure 54 and Figure 55). Given the minimal tumor uptakes observed for these complexes in
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the pretargeted biodistributions previously discussed, this is hardly surprising. This result is most
likely the result of lower in vivo stability and confirms that 99mTc-FK(PEG5-Tz)CR was an
appropriate choice as the lead compound.

Figure 46: “Pre-clicked” 99mTc-FK(Tz-TCO-A33)C (6 hrs) (Left to right: full scan; sagittal slice
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice
intersecting with tumor center).
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Figure 47: 99mTc-FK(Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan; sagittal
slice intersecting with tumor center; coronal slice intersecting with tumor center; axial slice
intersecting with tumor center).
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Figure 48: 99mTc-FK(Tz)C control (4 hrs) (Left to right: full scan; sagittal slice intersecting with
tumor center; coronal slice intersecting with tumor center; axial slice intersecting with tumor
center).

Figure 49: “Pre-clicked” 99mTc-FK(PEG5-Tz-TCO-A33)CR (8 hrs) (Left to right: full scan;
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial
slice intersecting with tumor center).
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Figure 50: 99mTc-FK(PEG5-Tz)CR and A33-TCO in vivo click (4 hrs) (Left to right: full scan;
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial
slice intersecting with tumor center).

Figure 51: 99mTc-FK(PEG5-Tz)CR control (4 hrs) (Left to right: full scan; sagittal slice
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice
intersecting with tumor center).
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Figure 52: 99mTc-DK(PEG5-Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan;
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial
slice intersecting with tumor center).

Figure 53: 99mTc-DK(PEG5-Tz)C control (4 hrs) (Left to right: full scan; sagittal slice
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice
intersecting with tumor center).
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Figure 54: 99mTc-SK(PEG5-Tz)C and A33-TCO in vivo click (4 hrs) (Left to right: full scan;
sagittal slice intersecting with tumor center; coronal slice intersecting with tumor center; axial
slice intersecting with tumor center).
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Figure 55: 99mTc-SK(PEG5-Tz)C control (4 hrs) (Left to right: full scan; sagittal slice
intersecting with tumor center; coronal slice intersecting with tumor center; axial slice
intersecting with tumor center).

5.7. Conclusion
The biological data obtained confirmed the in vivo “click” reaction for 99mTc-FK(Tz)C
and 99mTc-FK(PEG5-Tz)CR but not for 99mTc-DK(PEG5-Tz)C or 99mTc-SK(PEG5-Tz)C.
Although the tumor:intestinal uptake was significantly reduced for the lead complex, 99mTcFK(PEG5-Tz)CR, compared with the original complex tested, 99mTc-FK(Tz)C, it remained too
high for translation to the clinic.
The failure of 99mTc-DK(PEG5-Tz)C and 99mTc-SK(PEG5-Tz)C to produce SPECT/CT
images with well delineated tumors could be a function of their blood-half lives and/or in vivo
stability. 99mTc-DK(PEG5-Tz)C had a longer blood half-life than did 99mTc-FK(PEG5-Tz)CR, but
99m

Tc-SK(PEG5-Tz)C had a shorter blood-half-life. This indicates that the blood half-life could

explain the failure of 99mTc-SK(PEG5-Tz)C but not 99mTc-DK(PEG5-Tz)C. All of the pretargeted
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images showed activity in the thyroid, indicating at least some degradation. While this was
present for the lead complex as well as the failed complexes, it is possible that the 99mTcDK(PEG5-Tz)C and 99mTc-SK(PEG5-Tz)C degraded further than did 99mTc-FK(PEG5-Tz)CR,
removing enough 99mTc from the Tz-containing complex to preclude an effective in vivo “click.”
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Chapter 6
Summary
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A series 99mTc imaging agents with tri- or tetra-peptide N3S ligands and appended Tz
moieties were successfully synthesized and characterized along with their cold Re analogs. The
first complex tested in vivo, 99mTc-FK(Tz)C, successfully imaged an SW1222 xenografted tumor
pretargeted with A33-TCO. This was a promising result, but shared the high background
observed by Garcia et al. with 99mTc-HYNIC-Tz.115 The subsequent strategy to find a more
hydrophilic alternative, thereby promoting renal clearance and lowering intestinal uptake, was
successful with the lead complex, 99mTc-FK(PEG5-Tz)CR, as demonstrated by the Log P value
and the biodistributions in healthy and tumor-bearing mice. The other two complexes tested,
99m

T-DK(PEG5-Tz)C and 99mTc-SK(PEG5-Tz)C were more hydrophilic, but had lower

tumor:background uptake and could not delineate the tumors in pretargeted SPECT/CT images.
Despite the improved tumor:intestinal uptake (down to 1:16 for 99mTc-FK(PEG5-Tz)CR
from 1:40 %ID/g for 99mTc-FK(Tz)C), the SPECT/CT image was not greatly improved.
Consequently, the search for additional Tz-bearing 99mTc complexes with more favorable
characteristics is on-going.
Although this work did not produce a viable candidate for use in the clinic, it represents
one more example of a successful in vivo “click” that made use of the bioorthogonal IEDDA
reaction. The IEDDA reaction has made small molecule pretargeting considerably more
accessible and will continue to facilitate the development of now radiopharmaceuticals in the
years to come.
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Chapter 7
Future Work
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Future work will focus on finding 99mTc ligand systems that can both accommodate the
addition of a Tz moiety and provide more favorable pharmacokinetic and clearance
characteristics. If further peptide ligand systems are pursued, additional lysine residues as well as
more positively charged residues could promote renal clearance. Alternative Tz moieties can also
be explored to both improve clearance properties and in vivo stability.
Additionally, any ligand system developed should be compatible for use in a kit wherein
the Tz-bearing ligand would simply require the addition of 99mTcO4- under mild conditions for
ease of use in the clinic. With the pretargeting methodology already requiring a two-step
administration during treatment, any complex synthetic procedure would preclude translation.
Despite the difficulties that have been encountered in developing Tz-bearing 99mTc
imaging agents to take advantage of the IEDDA “click” reaction both by this group and others,
there is no reason to expect that these will not be overcome in due time. With the plethora of
99m

Tc complexes currently used in the clinic and the continued maturation of pretargeting, the

scientific and commercial possibilities of making use of IEDDA “click” reactions for improved
imaging will continue to be enticing, despite the benefits of PET imaging over SPECT imaging.
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